Aytu BioPharma (AYTU) 10-Q 16 May 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	9 Months Ended
	Mar. 31, 2022	May 09, 2022
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	373 Inverness Parkway
Entity Address, Address Line Two	Suite 206
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		38,574,875
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 27,613	$ 49,649
Restricted cash		252
Accounts receivable, net	27,613	28,176
Inventory, net	13,891	16,339
Prepaid expenses	7,942	9,780
Other current assets	888	1,038
Total current assets	77,947	105,234
Property and equipment, net	3,479	5,140
Operating lease right-of-use asset	3,561	3,563
Intangible assets, net	74,428	85,464
Goodwill	8,637	65,802
Other non-current assets	774	465
Total non-current assets	90,879	160,434
Total assets	168,826	265,668
Current liabilities
Accounts payable and other	11,130	19,255
Accrued liabilities	53,470	51,295
Accrued compensation	5,258	5,939
Short-term line of credit	3,385	7,934
Current portion of debt	100	16,668
Current portion of operating lease liabilities	1,203	940
Current portion of fixed payment arrangements	2,903	3,134
Current portion of CVR liabilities	156	218
Current portion of contingent consideration		4,055
Other current liabilities	2,755
Total current liabilities	80,360	109,438
Debt, net of current portion	14,167	180
Operating lease liabilities, net of current portion	2,406	2,624
Fixed payment arrangements, net of current portion	4,237	6,324
CVR liabilities, net of current portion	564	1,177
Contingent consideration, net of current portion	371	8,002
Other non-current liabilities	5,577	355
Total liabilities	107,682	128,100
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of March 31, 2022 and June 30, 2021
Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 33,355,935 and 27,490,412, respectively, as of March 31, 2022 and June 30, 2021	3	3
Additional paid-in capital	331,912	315,864
Accumulated deficit	(270,771)	(178,299)
Total stockholders' equity	61,144	137,568
Total liabilities and stockholders' equity	$ 168,826	$ 265,668

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Preferred stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	33,355,935	27,490,412
Common stock, shares outstanding	33,355,935	27,490,412

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenues
Product revenue, net	$ 24,199	$ 13,483	$ 69,221	$ 42,150
Revenue from Contract with Customer, Product and Service	Product	Product	Product	Product
Cost of sales	$ 11,513	$ 13,935	$ 31,780	$ 24,249
Gross profit	12,686	(452)	37,441	17,901
Operating expenses
Research and development	3,726	390	10,742	859
Selling and marketing	9,743	6,597	28,700	18,128
General and administrative	7,615	6,001	23,784	16,948
Acquisition related costs		1,537		2,849
Restructuring costs		4,818		4,875
Impairment expense	45,196	4,286	64,649	4,286
Amortization of intangible assets	1,061	1,585	3,214	4,754
Total operating expenses	67,341	25,214	131,089	52,699
Loss from operations	(54,655)	(25,666)	(93,648)	(34,798)
Other income (expense)
Other income/(expense), net	(55)	(425)	(75)	(1,555)
Gain (loss) from contingent consideration	1,257	631	761	(2,680)
Gain (loss) on extinguishment of debt	169		169	(258)
Gain on derivative warrant liability	211		211
Total other expense	1,582	206	1,066	(4,493)
Loss before income tax	(53,073)	(25,460)	(92,582)	(39,291)
Income tax benefit			(110)
Net loss	$ (53,073)	$ (25,460)	$ (92,472)	$ (39,291)
Weighted average number of common shares outstanding - basic (in shares)	29,689,856	18,092,465	27,211,708	14,490,219
Weighted average number of common shares outstanding - diluted (in shares)	29,689,856	18,092,465	27,211,708	14,490,219
Basic net loss per common share (in dollars per share)	$ (1.79)	$ (1.41)	$ (3.40)	$ (2.71)
Diluted net loss per common share (in dollars per share)	$ (1.79)	$ (1.41)	$ (3.40)	$ (2.71)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2020	$ 1	$ 215,024	$ (120,010)	$ 95,015
Beginning balance (in shares) at Jun. 30, 2020	12,583,736
Net loss			(39,291)	(39,291)
Stock-based compensation		2,345		2,345
Issuance of stock for business acquisition, net of issuance costs	$ 1	53,102		53,103
Issuance of stock for business acquisition, net of issuance costs (in shares)	5,471,804
Issuance of common stock, net of cash issuance costs	$ 1	29,487		29,488
Issuance of common stock, net of cash issuance costs (in shares)	5,169,076
Issuance of preferred, common stock related to debt conversion, amount		1,058		1,058
Issuance of preferred, common stock related to debt conversion, shares	130,081
Estimated fair value of replacement equity awards		432		432
Issuance of common stock for CVRs payout		1,000		1,000
Issuance of common stock for CVRs payout (in shares)	103,190
Ending balance at Mar. 31, 2021	$ 3	302,448	(159,301)	143,150
Ending balance (in shares) at Mar. 31, 2021	23,457,887
Beginning balance at Dec. 31, 2020	$ 2	246,532	(133,841)	112,693
Beginning balance (in shares) at Dec. 31, 2020	17,882,893
Net loss			(25,460)	(25,460)
Stock-based compensation		1,382		1,382
Issuance of stock for business acquisition, net of issuance costs	$ 1	53,102		53,103
Issuance of stock for business acquisition, net of issuance costs (in shares)	5,471,804
Estimated fair value of replacement equity awards		432		432
Issuance of common stock for CVRs payout		1,000		1,000
Issuance of common stock for CVRs payout (in shares)	103,190
Ending balance at Mar. 31, 2021	$ 3	302,448	(159,301)	143,150
Ending balance (in shares) at Mar. 31, 2021	23,457,887
Beginning balance at Jun. 30, 2021	$ 3	315,864	(178,299)	137,568
Beginning balance (in shares) at Jun. 30, 2021	27,490,412
Net loss			(92,472)	(92,472)
Stock-based compensation		4,018		4,018
Stock-based compensation (in shares)	404,739
Warrants issued with debt refinance		379		379
Issuance of common stock, net of cash issuance costs		11,659		11,659
Issuance of common stock, net of cash issuance costs (in shares)	5,460,784
Tax withholding for stock-based compensation		(8)		(8)
Ending balance at Mar. 31, 2022	$ 3	331,912	(270,771)	61,144
Ending balance (in shares) at Mar. 31, 2022	33,355,935
Beginning balance at Dec. 31, 2021	$ 3	323,231	(217,698)	105,536
Beginning balance (in shares) at Dec. 31, 2021	30,010,468
Net loss			(53,073)	(53,073)
Stock-based compensation		1,270		1,270
Stock-based compensation (in shares)	107,767
Warrants issued with debt refinance		379		379
Issuance of common stock, net of cash issuance costs		7,034		7,034
Issuance of common stock, net of cash issuance costs (in shares)	3,237,700
Tax withholding for stock-based compensation		(2)		(2)
Ending balance at Mar. 31, 2022	$ 3	$ 331,912	$ (270,771)	$ 61,144
Ending balance (in shares) at Mar. 31, 2022	33,355,935

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Activities
Net loss	$ (92,472)	$ (39,291)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	8,005	5,878
Impairment expense	64,649	4,286
Stock-based compensation expense	4,018	2,485
(Gain) loss from contingent considerations	(761)	2,680
Amortization of senior debt (premium) discount	(268)	115
(Gain) loss on sale of equipment	(44)	112
Gain on termination of lease		(343)
(Gain) loss on debt extinguishment	(193)	258
Inventory write-down	352	7,227
Gain on derivative warrant liability	(211)
Other noncash adjustments	(152)	335
Changes in operating assets and liabilities:
Accounts receivable	647	1,764
Inventory	91	(4,390)
Prepaid expenses and other current assets	1,406	7,673
Accounts payable and other	(8,099)	(6,156)
Accrued liabilities	1,252	(2,293)
Other operating assets and liabilities, net	52	(27)
Net cash used in operating activities	(21,728)	(19,687)
Investing Activities
Contingent consideration payment	(3,138)	(683)
Cash received from acquisition		15,722
Cash payment for business acquisition		(15,399)
Other investing activities	(69)	4
Net cash used in investing activities	(3,207)	(356)
Financing Activities
Proceeds from issuance of stock	12,700	32,250
Payment of stock issuance costs	(782)	(4,430)
Payment made to fixed payment arrangement	(3,277)	(3,034)
Proceeds from short-term line of credit	112,463
Payments made on short-term line of credit	(117,012)	(5,968)
Payments made to borrowings	(16,075)	(318)
Proceeds from borrowings	15,000
Payment for debt issuance costs	(363)
Other financing activities	(7)
Net cash provided by financing activities	2,647	18,500
Net change in cash, restricted cash and cash equivalents	(22,288)	(1,543)
Cash, cash equivalents and restricted cash at beginning of period	49,901	48,333
Cash, cash equivalents and restricted cash at end of period	27,613	46,790
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	27,613	46,538
Restricted cash		252
Total cash, cash equivalents and restricted cash	27,613	46,790
Supplemental cash flow data
Cash paid for interest	3,080	449
Non-cash investing and financing activities:
Warrants issued	3,177	1,628
Other noncash investing and financing activities	$ 473	66
Fixed payment arrangements included in accrued liabilities		1,575
Issuance of common stock for note conversion		1,058
Contingent value rights payout		1,000
Issuance related to acquisition of Neos		53,241
Fair value of non-cash assets acquired		104,322
Fair value of liabilities assumed		88,700
Estimated fair value of replacement equity awards		$ 432

Nature of Business, Financial C

Nature of Business, Financial Condition, Basis of Presentation	9 Months Ended
	Mar. 31, 2022
Nature of Business, Financial Condition, Basis of Presentation
Nature of Business, Financial Condition, Basis of Presentation	1. Nature of Business, Financial Condition, Basis of Presentation Aytu BioPharma, Inc. (“Aytu”, the “Company” or “we”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products and developing therapeutics for rare pediatric-onset or difficult-to-treat diseases. The Company operates through two business segments (i) the BioPharma segment, consisting of prescription pharmaceutical products (the “Rx Portfolio”) and (ii) the Consumer Health segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome (“VEDS”) and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections. The Company was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, the Company changed its name to Aytu BioPharma, Inc. The Rx Portfolio primarily consists of (i) Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”), (ii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and (iii) Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of over twenty consumer health products competing in large healthcare categories, including diabetes management, pain management, digestive health, sexual and urological health and general wellness, commercialized through direct-to-consumer and e-commerce marketing channels. The Company’s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets, while also developing a therapeutic pipeline focused on rare pediatric-onset conditions and difficult-to-treat diseases. As of March 31, 2022, the Company had approximately $27.6 million of cash and cash equivalents. The Company’s operations have historically consumed cash and are expected to continue to consume cash. The Company incurred a net loss of approximately $53.1 million and $25.5 million during the three months ended March 31, 2022 and 2021, respectively, and $92.5 million and $39.3 million for the nine months ended March 31, 2022 and 2021, respectively. The Company had an accumulated deficit of $270.8 million and $178.3 million as of March 31, 2022 and June 30, 2021, respectively. Cash used in operations was $21.7 million and $19.7 million during the nine months ended March 31, 2022 and 2021, respectively. As the Company does not have sufficient cash and cash equivalents as of March 31, 2022 to cover its cash needs for the twelve months following the filing date of this Quarterly Report on Form 10-Q, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on raising additional capital through public or private equity or debt offerings or monetizing assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities and delay the progress of its developmental product candidates or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern. Basis of Presentation.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Prior Period Reclassification Certain prior year amounts in the consolidated balance sheets, statements of earnings and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of the U.S. Food and Drug Administration (the “FDA”) fees for commercialized products. This was previously included in general and administrative expenses and is currently recorded as a component of cost of sales on the condensed consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the three and nine months ended March 31, 2022 and 2021 or its financial position as of March 31, 2022 or June 30, 2021. Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the nine months ended March 31, 2022. The impairment of goodwill during the three months ended September 30, 2021 decreased net deferred tax liability by $0.1 million resulting in an income tax benefit of $0.1 million during the three months ended September 30, 2021. The income tax provision did not impact the amount of deferred taxes due to a full valuation allowance and the goodwill being recorded as a deferred tax liability. Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective March 31, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial position and results of operations. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2021. There have been no significant changes to the Company’s significant accounting policies during the nine months ended March 31, 2022.

Acquisitions

Acquisitions	9 Months Ended
	Mar. 31, 2022
Acquisitions
Acquisitions	3. Acquisitions Neos Acquisition On March 19, 2021, the Company acquired Neos, a commercial-stage pharmaceutical company. Neos merged into, a subsidiary of the Company with and all outstanding Neos common stock was exchanged for approximately 5,472,000 shares of the Company’s common stock (“the Neos Acquisition”). The Company incurred (i) approximately $2.9 million of acquisition related costs, recognized as part of operating expense, and (ii) $0.1 million of issuance costs, recognized as a component of stockholders’ equity. The following table summarizes the fair value of assets acquired and liabilities assumed; ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands, except share and per-share) Considerations: ​ ​ ​ Fair Value of Aytu Common Stock ​ ​ ​ Total shares issued at close ​ 5,471,804 Fair value per share of Aytu common stock $ 9.73 Fair value of equity consideration transferred $ 53,241 Cash ​ ​ 15,383 Estimated fair value of replacement equity awards ​ ​ 432 Total consideration transferred $ 69,056 ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Total consideration transferred $ 69,056 Recognized amounts of identified assets acquired and liabilities assumed ​ ​ ​ Cash and cash equivalents $ 15,722 Accounts receivable ​ ​ 24,696 Inventory ​ ​ 10,984 Prepaid expenses and other current assets ​ ​ 2,929 Operating leases right-to-use assets ​ ​ 3,515 Property, plant and equipment ​ ​ 5,519 Intangible assets ​ ​ 56,530 Other long-term assets ​ ​ 149 Accounts payable and accrued expenses ​ ​ (56,718) Short-term line of credit ​ ​ (10,707) Long-term debt, including current portion ​ ​ (17,678) Operating lease liabilities ​ ​ (3,515) Other long-term liabilities ​ ​ (82) Total identifiable net assets ​ 31,344 Goodwill $ 37,712 ​ The fair value of the identifiable intangible assets acquired were as follows: ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Identified intangible assets acquired: ​ ​ ​ Developed technology right $ 30,200 Developed products technology ​ ​ 22,700 In-process R&D ​ ​ 2,600 RxConnect ​ ​ 630 Trade name ​ ​ 400 Total intangible assets acquired $ 56,530 ​ The fair value of the Neos trade name, in-process R&D and developed product technology, which is the proprietary technology for the development of Adzenys XR-ODT, Adzenys ER, Cotempla XR-ODT and generic Tussionex, were determined using the relief from royalty method. The fair value of developed technology right, which is a proprietary modified-release drug delivery technology, was determined using multi-period excess earnings method. The fair value of RxConnect was determined using cost to recreate method. The finite-lived intangible assets are being amortized over a range of between 1 to 17 years. Unaudited Pro Forma Information The following supplemental unaudited proforma financial information presents the Company’s results as if the Neos Acquisition had occurred on July 1, 2020. The unaudited pro forma results have been prepared based on estimates and assumptions, which management believes are reasonable; however, the results are not necessarily indicative of the consolidated results of operations had the acquisition occurred on July 1, 2020, or of future results of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2022 2021 ​ ​ ​ ​ Pro forma ​ ​ Unaudited Unaudited ​ ​ (In thousands) Total revenues, net ​ $ 69,221 ​ $ 74,582 Net loss ​ $ (92,472) ​ $ (55,712) ​ Rumpus Acquisition On April 12, 2021, the Company entered into an asset purchase agreement with Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, Rumpus Vascular, LLC (together “Rumpus”) pursuant to which the Company acquired commercial global licenses, relating primarily to the pediatric-onset rare disease development asset enzastaurin, or AR101. AR101 is initially being studied for the treatment of VEDS. This asset was acquired for an up-front fee of $1.5 million in cash and payment of aggregated fees of $0.6 million. Upon the achievement of certain regulatory and commercial milestones, the Company is obliged to pay up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option. AR101 is an orally available investigational small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways (see Note 13 – Commitments and Contingencies).

Revenue Recognition

Revenue Recognition	9 Months Ended
	Mar. 31, 2022
Revenue Recognition
Revenue Recognition	4. Revenue Recognition Contract Balances The Company disaggregates its revenue into three product portfolios. The primary care portfolio is composed of ZolpiMist and Tuzistra. The pediatric portfolio is composed of Adzenys XR-ODT, Cotempla XR-ODT Poly-Vi-Flor, Tri-Vi-Flor, Karbinal ER and a generic Tussionex. The Consumer Health portfolio is composed of over twenty consumer health products competing in large healthcare categories. As part of the realization of post-acquisition synergies and product prioritization, the Company has implemented a portfolio rationalization plan whereby it will discontinue or divest non-core products including Cefaclor, Flexichamber, Tussionex, Tuzistra XR, and Zolpimist, effectively eliminating the primary care portfolio. These products, collectively, contributed $1.7 million in net revenue and $0.6 million in gross loss during the nine months ended March 31, 2022 (see Note 8 – Goodwill and Other Intangible Assets). Revenues by Product Portfolio. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) Primary care portfolio $ 272 $ 1,209 $ 889 $ 8,339 Pediatric portfolio ​ ​ 13,590 ​ ​ 3,918 ​ ​ 41,499 ​ ​ 9,752 Consumer Health portfolio ​ ​ 10,337 ​ ​ 8,356 ​ ​ 26,833 ​ ​ 24,059 Consolidated revenue $ 24,199 $ 13,483 $ 69,221 $ 42,150 ​ ​ Revenues by Geographic location . ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) U.S. ​ $ 23,755 ​ $ 12,344 ​ $ 67,408 ​ $ 38,245 International ​ 444 ​ 1,139 ​ 1,813 ​ 3,905 Total net revenue ​ $ 24,199 ​ $ 13,483 ​ $ 69,221 ​ $ 42,150 ​

Inventories

Inventories	9 Months Ended
	Mar. 31, 2022
Inventories
Inventories	5. Inventories Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period that the impairment is first recognized. The Company incurred charges of $2.0 million and $7.0 million of inventory during the three months ended March 31, 2022 and 2021, respectively, and $2.4 million and $7.2 million during the nine months ended March 31, 2022 and 2021, respectively. In the three and nine months ended March 31, 2022, the inventory charge of $2.0 million was related to the decision to discontinue or divest certain non-core products (see Note 4 – Revenue Recognition and Note 8 – Goodwill and Other Intangible Assets). The write-down for each of the three and nine months ended March 31, 2021 was primarily due to the changing market conditions for the Company’s Covid-19 test kits. Inventory balances consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ (In thousands) Raw materials $ 1,796 $ 2,269 Work in process ​ ​ 2,222 ​ ​ 3,346 Finished goods ​ 9,873 ​ 10,724 Inventory, net ​ $ 13,891 ​ $ 16,339 ​

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2022
Property and Equipment
Property and Equipment	6. Property and Equipment Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,139 $ 3,070 Leasehold improvements 999 ​ 959 Office equipment, furniture and other 1,120 ​ 1,093 Lab equipment 832 ​ 832 Assets under construction 129 ​ 198 Property and equipment, gross ​ ​ 5,219 ​ ​ 6,152 Less accumulated depreciation and amortization ​ ​ (1,740) ​ ​ (1,012) Property and equipment, net $ 3,479 ​ $ 5,140 ​ ​ Depreciation and amortization expense was $0.5 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively, and $1.3 million and $0.1 million for the nine months ended March 31, 2022 and 2021, respectively. During the nine months ended March 31, 2022 and 2021, the Company recognized a gain of $44,000 and a loss of $0.1 million on the disposal of equipment, respectively. During the three and nine months ended March 31, 2022, in connection with the decision to divest Tussionex, the Company recorded a $0.2 million impairment charge related to manufacturing equipment associated with this product. There was no such impairment expense during the three and nine months ended March 31, 2021.

Leases

Leases	9 Months Ended
	Mar. 31, 2022
Leases
Leases	7. Leases The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between 2022 and 2024. Most leases include one or more options to renew and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. For purposes of calculating operating lease liabilities, lease terms are deemed not to include options to extend the lease until it is reasonably certain that the Company will exercise that option. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability In May 2021, the Company entered into a commercial lease agreement for 6,352 square feet of office in Berwyn, Pennsylvania that was to commence on December 1, 2021 and end on January 31, 2025. On July 19, 2021, the Company and the lessor amended the agreement to move the commencement date from December 1, 2021 to September 1, 2021. The Company recorded an operating lease ROU asset and lease liabilities of $0.5 million in the consolidated balance sheet representing the present value of minimum lease payments using an estimated borrowing rate of 6.25%. In October 2021, the Company’s Innovus subsidiary entered into a commercial lease agreement for 6,580 square feet of warehouse in Oceanside, California that commenced on December 1, 2021 and ends on December 31, 2026. The Company recorded an operating lease ROU asset and lease liabilities of $0.3 million in the consolidated balance sheet representing the present value of minimum lease payments using Innovus’ estimated borrowing rate of 18.0%. The components of lease expenses are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ ​ March 31, ​ March 31, ​ ​ ​ 2022 2021 2022 2021 Statement of Operations Classification ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 316 ​ $ 70 ​ $ 942 ​ $ 195 Operating expenses Short-term lease cost 65 ​ 9 ​ 130 ​ 14 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets 18 ​ 19 ​ 55 ​ 19 Cost of sales Interest on lease liabilities ​ ​ 3 ​ ​ 1 ​ ​ 11 ​ ​ 1 ​ Other (expense), net Total net lease cost $ 402 ​ $ 99 ​ $ 1,138 ​ $ 229 ​ ​ Supplemental balance sheet information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, Balance Sheet Classification ​ ​ 2022 ​ 2021 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 3,561 ​ $ 3,563 Operating lease right-of-use asset Finance lease assets ​ ​ 274 ​ 329 Property and equipment, net, net Total leased assets ​ $ 3,835 ​ $ 3,892 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,203 ​ $ 940 ​ Current portion of operating lease liabilities Finance leases ​ ​ 100 ​ ​ 102 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 2,406 ​ ​ 2,624 ​ Operating lease liabilities, net of current portion Finance leases ​ ​ 106 ​ ​ 180 ​ Debt, net of current portion Total lease liabilities ​ $ 3,815 ​ $ 3,846 ​ ​ ​ ​ Remaining lease term and discount rate used are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.86 ​ ​ 3.42 ​ Finance lease assets ​ 1.98 ​ ​ 2.72 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.44 % ​ 6.62 % Finance lease assets ​ ​ 6.43 % ​ 6.41 % ​ ​ Supplemental cash flow information related to lease is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2022 2021 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 942 ​ $ 195 Operating cash flows from finance leases ​ $ 12 ​ $ 1 Financing cash flows from finance leases ​ $ 76 ​ $ 3 ​ ​ As of March 31, 2022, the maturities of the Company’s future minimum lease payments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2022 (remaining 3 months) ​ $ 357 ​ $ 29 2023 ​ ​ 1,436 ​ ​ 104 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 4,057 ​ ​ 220 Less: Imputed interest ​ ​ (448) ​ ​ (14) Lease liabilities ​ $ 3,609 ​ $ 206 ​

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Mar. 31, 2022
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets	8. Goodwill and Other Intangible Assets During fiscal 2022, the Company’s market capitalization has significantly declined. During the three months ended September 30, 2021, the decline was considered a qualitative factor that led management to assess whether an impairment had occurred. Management’s evaluation indicated that the goodwill related to one of its reporting units within the BioPharma segment was potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. As of September 30, 2021, utilizing the risk adjusted weighted-average discount rate, the fair value of the reporting unit was less than its carrying value. The Company recognized an impairment loss of $19.5 million in the BioPharma segment related to the goodwill associated with the Cerecor Inc. acquisition. As of September 30, 2021, a quantitative test indicated there was no impairment to the Consumer Health reporting unit as it resulted in an implied fair value of $5.9 million compared with the $0.5 million carrying value. During the three months ended March 31, 2022, the continued decline of the Company’s market capitalization was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management’s evaluation indicated that the goodwill related to one of its reporting units within the BioPharma segment was potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. As of March 31, 2022, utilizing the risk adjusted weighted-average discount rate, the fair value of the reporting unit was less than its carrying value. The Company recognized an impairment loss of $37.7 million in the BioPharma segment related to the goodwill associated with the Neos Acquisition. The Consumer Health segment, which has $8.6 million goodwill from the February 2020 acquisition of Innovus Pharmaceuticals, Inc. (the “Innovus Acquisition”), reported $2.2 million negative carrying value as of March 31, 2022, and as such there was no goodwill impairment during the three months ended March 31, 2022. The change in carrying amount of goodwill by reportable segment is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BioPharma Consumer Health Consolidated ​ ​ (In thousands) Balance as of June 30, 2021 ​ $ 57,165 ​ $ 8,637 ​ $ 65,802 Goodwill impairment ​ (19,453) ​ — ​ (19,453) Balance as of September 30, 2021 ​ ​ 37,712 ​ ​ 8,637 ​ ​ 46,349 Goodwill impairment ​ ​ — ​ ​ — ​ ​ — Balance as of December 31, 2021 ​ ​ 37,712 ​ ​ 8,637 ​ ​ 46,349 Goodwill impairment ​ ​ (37,712) ​ — ​ (37,712) Balance as of March 31, 2022 ​ $ — ​ $ 8,637 ​ $ 8,637 ​ The Company currently holds the following intangible asset portfolios as of March 31, 2022: (i) Product technology rights, acquired from the November 1, 2019 acquisition of a line of prescription pediatric products (“Pediatric Portfolio”) from Cerecor, Inc. and the Neos Acquisition in March 2021; (ii) Proprietary modified-release drug delivery technology right as a result of the Neos Acquisition; (iii) Acquired product distribution rights and commercial technology consisting of RxConnect and trade names as a result of the Neos Acquisition, and patents, trade names and the acquired customer lists from the Innovus Acquisition; (iv) Acquired in-process R&D from the Neos Acquisition related to the NT0502 product candidate for the treatment of sialorrhea. The following table provides the summary of the Company’s intangible assets as of March 31, 2022 and June 30, 2021, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,778) ​ $ (1,468) ​ $ — ​ — Acquired product technology right ​ 45,400 ​ (6,864) ​ (3,224) ​ 35,312 12.21 Acquired technology right ​ ​ 30,200 ​ ​ (1,834) ​ ​ — ​ ​ 28,366 ​ 16.00 Acquired product distribution rights ​ 11,354 ​ (3,204) ​ — ​ 8,150 7.85 Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (630) ​ ​ — ​ ​ — ​ — Acquired trade name ​ ​ 400 ​ ​ (206) ​ ​ (194) ​ ​ — ​ — Acquired customer lists ​ 390 ​ (390) ​ — ​ — — Total ​ $ 94,220 ​ $ (14,906) ​ $ (4,886) ​ $ 74,428 13.21 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,430) ​ $ 1,816 ​ 3.92 Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (178) ​ ​ 452 ​ 0.75 Acquired trade name ​ ​ 400 ​ ​ (56) ​ ​ 344 ​ 1.75 Acquired customer lists ​ ​ 390 ​ ​ (358) ​ ​ 32 ​ 0.01 Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​ ​ ​ The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: ​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2022 (remaining 3 months) ​ $ 1,624 2023 ​ ​ 6,490 2024 ​ ​ 6,477 2025 ​ ​ 6,282 2026 ​ ​ 5,938 2027 ​ ​ 5,908 Thereafter ​ ​ 39,109 Total future amortization expense ​ $ 71,828 ​ Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $2.0 million and $1.7 million for the three months ended March 31, 2022 and 2021, respectively, and $6.1 million and $4.9 million for the nine months ended March 31, 2022 and 2021, respectively. During the three and nine months ended March 31, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the BioPharma segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million impairment expense for the write-down of intangible assets consisting of (i) $2.6 million for AcipHex, (ii) $1.4 million for ZolpiMist, (iii) $0.5 million for Tussionex, (iv) $0.2 million for Cefaclor and (v) $0.2 million for the Neos tradename. During the three and nine months ended March 31, 2021, in connection with the divestiture of Natesto, the Company recorded $4.3 million impairment expense as a result of the impairment of the associated licensed intangible asset.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Mar. 31, 2022
Accrued Liabilities
Accrued Liabilities	9. Accrued liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Accrued program liabilities ​ $ 12,058 ​ $ 8,689 Accrued product-related fees ​ 1,997 ​ 2,501 Accrued savings offers ​ ​ 17,853 ​ ​ 20,148 Accrued distributor fees ​ ​ 5,303 ​ ​ 2,710 Accrued liabilities for trade partners ​ 2,003 ​ 5,421 Accrued option exercise and milestone fees ​ ​ 3,257 ​ ​ 600 Medicaid liabilities ​ 1,487 ​ 1,714 Return reserve ​ 5,969 ​ 6,367 Other accrued liabilities* ​ 3,543 ​ 3,145 Total accrued liabilities ​ $ 53,470 ​ $ 51,295 *

Line of Credit

Line of Credit	9 Months Ended
	Mar. 31, 2022
Line of Credit
Line of Credit	10. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued at variable interest through maturity at the one-month London Interbank Offered Rate (“LIBOR”), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 11 below, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. The Company incurred $0.1 million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $0.1 million as of March 31, 2022 was included in other noncurrent assets in the condensed consolidated balance sheets. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least five The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of March 31, 2022, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $0.1 million and $0.4 million for the three and nine months ended March 31, 2022, respectively. Interest expense was $28,000 for the period beginning March 19, 2021, the date the Neos Acquisition was closed, through March 31, 2021. As of March 31, 2022 and June 30, 2021, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $3.4 million and $7.9 million, respectively.

Long-term Debt

Long-term Debt	9 Months Ended
	Mar. 31, 2022
Long-term Debt
Long-term Debt	11. Long-term Debt Deerfield Debt. The Company evaluated and determined that the fair value of the remaining outstanding debt was $17.4 million as of the March 19, 2021 acquisition date. Accordingly, the Company recorded a premium of $0.8 million, which was the difference between carrying amount and the fair value of the debt and was being amortized into interest expense using the effective interest method over the remaining term of the debt. On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $0.2 million during the three months ended March 31, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $0.8 million for the period from July 1, 2021 through full repayment on January 26, 2022. Avenue Capital Loan: Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided, as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional six months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding debit being recorded as debt discount. The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of March 31, 2022, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $1.21 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $1.21 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception and through the reclassification to equity on March 7, 2022, the Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants was $0.6 million on January 26, 2022, with the corresponding debit being recorded as debt discount. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 14 – Capital Structure, at an offering price of $1.25 per share. As this offering precludes the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 867,769 at an exercise price of $1.21. As a result, on March 7, 2022, the Company reclassified the Avenue Capital Warrants from a liability to equity and recorded the $0.4 million fair value as additional paid in capital in stockholders’ equity in the Company’s financial statements. In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 15.37%. Total interest expense on the Avenue Capital loan, including debt discount amortization, was $0.4 million for the three months ended March 31, 2022. Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ March 31, ​ ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,577) Financing leases, maturing through May 2024 ​ ​ 206 Total debt ​ ​ 14,267 Less: current portion ​ ​ (100) Non-current portion of debt ​ $ 14,167 ​ Future principal payments of long-term debt, including financing leases, are as follows: ​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2022 ​ $ 100 2023 ​ ​ 5,924 2024 ​ ​ 9,820 Future principal payments ​ ​ 15,844 Less unamortized discount and issuance costs ​ ​ (1,577) Less current portion ​ ​ (100) Non-current portion of debt ​ $ 14,167 ​

Fair Value Considerations

Fair Value Considerations	9 Months Ended
	Mar. 31, 2022
Fair Value Considerations
Fair Value Considerations	12. Fair Value Considerations The Company’s asset and liability classified financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant derivative liability and contingent consideration. The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on Monte-Carlo models. The valuation policies are determined by management, and the Company’s Board of Directors is informed of any policy change. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s assets and liabilities are measured at fair value on a recurring basis and are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques discussed below in all periods presented. Recurring Fair Value Measurements The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2022 and June 30, 2021, by level within the fair value hierarchy. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at March 31, 2022 ​ Fair Value at March 31, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 27,613 ​ $ 27,613 ​ $ — ​ $ — Total ​ $ 27,613 $ 27,613 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ 371 $ — $ — $ 371 CVR liability ​ 720 ​ — ​ — ​ 720 Total ​ $ 1,091 $ — $ — ​ $ 1,091 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 49,649 ​ $ 49,649 ​ $ — ​ $ — Total ​ $ 49,649 $ 49,649 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 12,057 $ — $ — $ 12,057 CVR liability ​ ​ 1,395 ​ — ​ — ​ 1,395 Total ​ $ 13,452 $ — $ — ​ $ 13,452 ​ Contingent Consideration. Tuzistra The royalty and make-whole milestone payments related to the licensing agreements with TRIS Pharma, Inc. (“Tris”) for Tuzistra XR was being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 4 – Revenue Recognition), and ongoing negotiations with Tris, the Company has concluded that, as of March 31, 2022, the product milestone payments underlying the contingent consideration liability ceased to exist. As of March 31, 2022, the Company reversed the remaining contingent considerations liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris (see Note 20 – Subsequent Events) for termination of the Tuzistra licensing agreement. The amount is included in other current and noncurrent liabilities in the consolidated balance sheets, and represents the present value of future payments discounted using the Company’s borrowing rate. The Company deferred recognition of $0.9 million net gain from reversal of contingent consideration liability and the settlement payments until the termination of the original agreement and signing of the settlement agreement in May 2022, and was included in accrued liabilities in the consolidated balance sheets as of March 31, 2022. ZolpiMist The royalty payments related to the licensing agreements with Magna Pharmaceuticals, Inc. (“Magna”) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company has concluded that, as of March 31, 2022, the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. As of March 31, 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liability in the consolidated balance sheets. The Company recognized $0.6 million gain from reversal of contingent consideration liability and the termination payment in the consolidated statements of operations for the three and nine months ended March 31, 2022. On February 14, 2020, the Company recognized approximately $0.2 million in product related contingent consideration as a result of the February 14, 2020 Innovus Acquisition. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. As of March 31, 2022 and June 30, 2021, the contingent consideration balance was $0.3 million. In June 2017, Innovus entered into the Exclusive License Agreement with University of Iowa Research Foundation (“UIRD”) (the “UIRD Agreement”) for the use of patent and technology know-how as defined in the agreement. Pursuant to the agreement, Innovus will pay UIRD a milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payments of $0.2 million. The fair value was determined as the discounted value of the future contingent payment using a 26% discount rate based on the estimated risk that the milestones would be achieved. The discounted value as of March 31, 2022 and June 30, 2021, was approximately $0.1 million. As a result of the reversal of contingent consideration liabilities, there was no gain or loss from the change in fair value of contingent consideration during the three months ended March 31, 2022. During the three months ended March 31, 2021, the Company recognized a net gain of $0.7 million from the changes in fair values of contingent considerations. During the nine months ended March 31, 2022 and 2021, the Company recognized a loss of $0.5 million and $1.7 million, respectively, from the changes in fair values of contingent considerations. The total accretion expense related to these contingent considerations was approximately $23,000 and $15,000 during the three months ended March 31, 2022 and 2021, respectively, and $0.1 million and $0.3 million during the nine months ended March 31, 2022 and 2021, respectively. Contingent value rights. Warrants. Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Warrant ​ ​ Liability ​ Consideration ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2021 $ 1,395 ​ $ 12,057 ​ $ — Included in earnings ​ (675) ​ ​ 579 ​ ​ (211) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 590 Settlements * — ​ (12,265) ​ (379) Balance as of March 31, 2022 $ 720 ​ $ 371 ​ $ — * Including $9.1 million reversal of contingent consideration liabilities and $0.4 million liability warrants reclassified to equity Significant Assumptions Significant assumptions used in valuing CVRs were as follows: ​ ​ ​ ​ ​ ​ March 31, ​ 2022 Leveraged Beta 0.79 ​ Market risk premium ​ 6.22 % Risk-free interest rate ​ 2.12 % Discount ​ 19.50 % Company specific discount 10.00 % ​ Significant assumptions used in valuing the warrants were as follows: ​ ​ ​ ​ ​ ​ January 26, ​ 2022 Expected volatility 56.75 % Equivalent term (years) ​ 5.00 ​ Risk-free rate ​ 1.66 % Dividend yield ​ 0.00 % ​

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	13. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Company has two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first fixed obligation, the Company was to pay monthly payment of $86,400 beginning November 1, 2019 through January 2021, with a balloon payment of $15.0 million that was to be due in January 2021 (“Balloon Payment Obligation”). A second fixed obligation requires the Company pay a minimum of $100,000 monthly through February 2026, except for $210,767 paid in January 2020. On May 29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the “Early Payment Agreement”) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the six quarters commencing September 30, 2021. In addition, the Company acquired a Supply and Distribution Agreement with Tris (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Product Contingent Liability In February 2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the acquisition, Innovus is obligated to make five additional payments of $0.5 Pursuant to the UIRD Agreement, Innovus will pay to UIRD a total milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payment of $0.2 million. The discounted value as of March 31, 2022, is approximately $0.1 million. The first milestone cash payment of $50,000 was made in July 2021. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with JHU, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. On December 7, 2021, upon receiving Orphan Drug Designation (“ODD”) from the FDA for AR101, a milestone payment of $2.5 million is due and payable to Rumpus in cash or in shares of the Company’s common stock. The $2.5 million milestone payment is included in our accrued liabilities in the condensed consolidated balance sheets as of March 31, 2022, and was paid in full on April 1, 2022.

Capital Structure

Capital Structure	9 Months Ended
	Mar. 31, 2022
Capital Structure
Capital Structure	14. Capital Structure The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. As of March 31, 2022 and June 30, 2021, the Company had 33,355,935 and 27,490,412 common shares outstanding, respectively, and zero preferred shares outstanding, respectively. Included in the common stock outstanding are 2,241,089 shares of unvested restricted stock issued to executives, directors and employees. On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). As of March 31, 2022, approximately $43.0 million remains available under the 2020 Shelf. On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the nine months ended March 31, 2022, the Company issued an additional 2,430,784 shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $5.1 million before deducting underwriting discounts, commissions, and other offering expenses of $0.2 million. As of March 31, 2022, approximately $12.2 million of the Company’s common stock remained available to be sold pursuant to the ATM Sales Agreement. On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of March 31, 2022, approximately $92.4 million remain available under the 2021 Shelf. On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 3,030,000 shares of the Company’s common stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,030,000 shares of common stock, and (iii) common stock purchase warrants (the “Common Warrants”) to purchase up to 6,666,000 shares of common stock (the “March 2022 Offering”). The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase 1.1 shares of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants have an exercise price of $0.0001 per share of common stock and were exercised in full in April 2022. The Common Warrants have an exercise price of $1.30 per share of common stock and are exercisable six months after the date of issuance and have a term of five years from the date of exercisability. The Company raised gross proceeds of $7.6 million through the March 2022 Offering before commission and other costs of $0.8 million. The Pre-Funded and Common Warrants have a combined fair value of approximately $6.3 million and are classified as additional paid in capital in stockholders’ equity in the Company’s financial statements (see Note 16 - Warrants). On January 26, 2022, as consideration for entering into the Avenue Capital Agreement, the Company issued the Avenue Capital Warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $1.21 per share. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described above, at an offering price of $1.25 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of common stock issuable upon exercise of the Avenue Capital Warrants were set to 867,769 shares at an exercise price of $1.21. As a result, on March 7, 2022, the Company reclassified the Avenue Capital Warrants from a liability to equity and recorded the $0.4 million fair value as additional paid in capital in stockholders’ equity in the Company’s financial statements (see Note 11 – Long-term Debt and Note 12 – Fair Value Considerations).

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Mar. 31, 2022
Equity Incentive Plans
Equity Incentive Plans	15. Equity Incentive Plans Aytu 2015 Plan. Neos 2015 Plan. Stock Options Stock option activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 109,588 ​ $ 14.52 8.07 Forfeited/Cancelled (15,132) ​ ​ 8.03 Expired (10,599) ​ ​ 9.16 Outstanding at March 31, 2022 83,857 ​ $ 16.37 7.79 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at March 31, 2022 55,611 ​ $ 20.51 7.68 ​ As of March 31, 2022, there was $0.2 million total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.8 years. Restricted Stock During the nine months ended March 31, 2022, the Company granted a total of 295,000 shares of restricted stock, with certain accelerated vesting conditions, to pursuant to the Aytu 2015 Plan, of which 1/3 vest on the grant date and 1/12 on the first day of each quarter thereafter , subject to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $2.65 per-share to $4.02 per-share. Restricted stock activity under the Aytu 2015 Plan is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 1,955,268 ​ $ 7.83 Granted 295,000 ​ ​ 3.67 Vested (112,787) ​ ​ 8.03 Unvested at March 31, 2022 2,137,481 ​ $ 7.25 ​ As of March 31, 2022, there was $10.8 million total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.9 years. The Company previously issued 158 shares of restricted stock outside the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 100,000 shares of restricted stock to team outside of the Aytu 2015 Plan, of which 1/3 vest on January 17, 2023 and 1/12 each quarter thereafter , subject to continuing employment with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $1.35 per-share. As of March 31, 2022, there was total Restricted Stock Units During the nine months ended March 31, 2022, a total of 150,000 shares of restricted stock units (“RSUs”), to pursuant team to the Aytu 2015 Plan, of which 1/3 vest on the grant date and 1/12 on the first day of each quarter thereafter, subject to continuing employment with the Company through each vesting date. These RSUs have a grant date fair value ranging from $1.08 per-share to $1.86 per-share. RSUs activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 78,318 ​ $ 7.20 Granted ​ 150,000 ​ ​ 1.33 Vested (10,908) ​ ​ 6.50 Forfeited ​ (62,922) ​ ​ 7.44 Unvested at March 31, 2022 154,488 ​ $ 1.45 ​ As of March 31, 2022, there was $0.2 million total unrecognized compensation costs adjusted for any estimated forfeitures, related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.8 years. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the statements of operations as set forth in the below table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) Cost of sales ​ $ 7 ​ $ 9 ​ $ 24 ​ $ 9 Research and development ​ ​ 73 ​ ​ 3 ​ ​ 467 ​ ​ 3 Selling and marketing ​ ​ 23 ​ ​ 5 ​ ​ 51 ​ ​ 5 General and Administrative ​ 1,167 ​ 1,505 ​ 3,476 ​ 2,468 Total stock-based compensation expense ​ $ 1,270 ​ $ 1,522 ​ $ 4,018 ​ $ 2,485 ​

Warrants

Warrants	9 Months Ended
	Mar. 31, 2022
Warrants
Warrants	16. Warrants Equity Classified Warrants On March 7, 2022, the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 3,030,000 shares of the Company’s common stock, (ii) Pre-Funded Warrants to purchase up to 3,030,000 shares of common stock, and (iii) Common Warrants to purchase up to 6,666,000 shares of common stock. The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase 1.1 shares of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants have an exercise price of $0.0001 per share of common stock and were exercised in full in April 2022. The Common Warrants have an exercise price of $1.30 per share of common stock and are exercisable six months after the date of issuance and have a term of five years from the date of exercisability (see Note 14 – Capital Structure). On January 26, 2022, as consideration for entering into the Avenue Capital Agreement, the Company issued Avenue Capital Warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price of $1.21 per share, subject to adjustment. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants at an offering price of $1.25 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of common stock issuable upon exercise of the Avenue Capital Warrants were set to 867,769 shares at an exercise price of $1.21. As a result, on March 7, 2022, the Company reclassified the Avenue Capital Warrants from a liability to equity (see Note 11 – Long-term Debt, Note 12 – Fair Value Considerations and Note 14 – Capital Structure). Significant assumptions used in valuing these warrants were as follows: ​ ​ ​ ​ ​ ​ ​ March 7, ​ ​ 2022 Valuation method ​ Black-Scholes ​ Expected volatility 54.45 % Equivalent term (years) ​ 4.89 - 5.00 ​ Risk-free rate ​ 1.71 % Dividend yield ​ 0.00 % ​ On July 1, 2020, 92,302 warrants previously issued to a placement agent with a weighted average exercise price of $15.99 per warrant expired. In addition, during the nine months ended March 31, 2022, 31,925 various other warrants with a weighted average exercise price of $483.75 per warrant to purchase the Company’s shares of common stock expired. A summary of equity-based warrants is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 1,254,952 ​ $ 35.85 2.83 Warrants issued 10,563,769 ​ 0.92 5.37 Warrants expired (124,250) ​ 124.69 — Outstanding March 31, 2022 11,694,471 ​ $ 3.43 4.98 ​ Liability Classified Warrants As of March 31, 2022, the Company had 24,105 liability warrants outstanding with a weighted-average exercise price of $720.0 per share. These warrants expire on August 25, 2022.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Mar. 31, 2022
Net Loss Per Common Share
Net Loss Per Common Share	17. Net Loss per Common Share Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. The 3,030,000 Pre-Funded Warrants with an exercise price of $0.0001 per share of common stock were considered economically equivalent to common stock and were included in the weighted average number of common stock outstanding for calculation of basic income (loss) per share. The following table sets-forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ 2022 2021 Warrants to purchase common stock - liability classified (Note 16) ​ 24,105 24,105 Warrant to purchase common stock - equity classified (Note 16) ​ 8,664,471 1,257,525 Employee stock options (Note 15) ​ 83,857 136,254 Employee unvested restricted stock (Note 15) ​ 2,137,481 274,635 Employee unvested restricted stock units ​ (Note 15) ​ 154,488 ​ 87,362 Total ​ ​ ​ 11,064,402 1,779,881 ​

License Agreements

License Agreements	9 Months Ended
	Mar. 31, 2022
License Agreements
Licensing Agreements	18. License Agreements Healight In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to as NT0502. NT0502 is a new chemical entity that is being developed for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021. The royalties are recorded as cost of goods sold in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.

Segment Reporting

Segment Reporting	9 Months Ended
	Mar. 31, 2022
Segment Reporting
Segment Reporting	19. Segment Reporting The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two reportable segments: BioPharma and Consumer Health. The BioPharma segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products. Select financial information for these segments is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 ​ ​ (In thousands) ​ (In thousands) Consolidated revenue: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 13,862 ​ $ 5,127 ​ $ 42,388 ​ $ 18,091 Consumer Health ​ 10,337 ​ 8,356 ​ 26,833 ​ 24,059 Consolidated revenue ​ $ 24,199 ​ $ 13,483 ​ $ 69,221 ​ $ 42,150 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated net loss: ​ ​ ​ ​ BioPharma ​ $ (52,311) ​ $ (23,570) ​ $ (88,359) ​ $ (34,788) Consumer Health ​ (762) ​ (1,890) ​ (4,113) ​ (4,503) Consolidated net loss ​ $ (53,073) ​ $ (25,460) ​ $ (92,472) ​ $ (39,291) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 139,127 ​ $ 236,449 Consumer Health ​ 29,699 ​ 29,219 Consolidated assets ​ $ 168,826 ​ $ 265,668 ​

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2022
Subsequent Events
Subsequent Events	20. Subsequent Events On April 14, 2022, upon receiving Fast Track designation from the FDA for AR101, a milestone payment of $1.5 million is due and payable to Rumpus in cash or in shares of the Company’s common stock. In May 2022, the Company issued 2,188,940 shares of common stock and $75,000 in cash for the full repayment of the amount due under the Fast Track designation milestone. On April 19, 2022, the Company issued 3,030,000 shares of common stock to holders of the March 7, 2022 Pre-Funded Warrants upon exercise of these warrants at an exercise price of $0.0001. On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6 million to $9 million, which reduced our total liability for minimum payments by approximately $8 million from the original License Agreement. The settlement payment will be paid in three installments from December 2022 through July 2024.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Significant Accounting Policies
Basis of Presentation	Basis of Presentation.
Use of Estimates	Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Prior Period Reclassification	Prior Period Reclassification Certain prior year amounts in the consolidated balance sheets, statements of earnings and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of the U.S. Food and Drug Administration (the “FDA”) fees for commercialized products. This was previously included in general and administrative expenses and is currently recorded as a component of cost of sales on the condensed consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the three and nine months ended March 31, 2022 and 2021 or its financial position as of March 31, 2022 or June 30, 2021.
Income Taxes	Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the nine months ended March 31, 2022. The impairment of goodwill during the three months ended September 30, 2021 decreased net deferred tax liability by $0.1 million resulting in an income tax benefit of $0.1 million during the three months ended September 30, 2021. The income tax provision did not impact the amount of deferred taxes due to a full valuation allowance and the goodwill being recorded as a deferred tax liability.
Recent Accounting Pronouncements Not Yet Adopted	Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective March 31, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The Company does not expect the adoption of this standard to have a material impact on the Company’s consolidated financial position and results of operations. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2021. There have been no significant changes to the Company’s significant accounting policies during the nine months ended March 31, 2022.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2022
Acquisitions
Schedule of assets acquired and liabilities assumed	​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands, except share and per-share) Considerations: ​ ​ ​ Fair Value of Aytu Common Stock ​ ​ ​ Total shares issued at close ​ 5,471,804 Fair value per share of Aytu common stock $ 9.73 Fair value of equity consideration transferred $ 53,241 Cash ​ ​ 15,383 Estimated fair value of replacement equity awards ​ ​ 432 Total consideration transferred $ 69,056 ​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Total consideration transferred $ 69,056 Recognized amounts of identified assets acquired and liabilities assumed ​ ​ ​ Cash and cash equivalents $ 15,722 Accounts receivable ​ ​ 24,696 Inventory ​ ​ 10,984 Prepaid expenses and other current assets ​ ​ 2,929 Operating leases right-to-use assets ​ ​ 3,515 Property, plant and equipment ​ ​ 5,519 Intangible assets ​ ​ 56,530 Other long-term assets ​ ​ 149 Accounts payable and accrued expenses ​ ​ (56,718) Short-term line of credit ​ ​ (10,707) Long-term debt, including current portion ​ ​ (17,678) Operating lease liabilities ​ ​ (3,515) Other long-term liabilities ​ ​ (82) Total identifiable net assets ​ 31,344 Goodwill $ 37,712
Schedule of intangible assets acquired	​ ​ ​ ​ ​ ​ ​ March 19, 2021 ​ ​ (In thousands) Identified intangible assets acquired: ​ ​ ​ Developed technology right $ 30,200 Developed products technology ​ ​ 22,700 In-process R&D ​ ​ 2,600 RxConnect ​ ​ 630 Trade name ​ ​ 400 Total intangible assets acquired $ 56,530
Schedule of Pro forma information	​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2022 2021 ​ ​ ​ ​ Pro forma ​ ​ Unaudited Unaudited ​ ​ (In thousands) Total revenues, net ​ $ 69,221 ​ $ 74,582 Net loss ​ $ (92,472) ​ $ (55,712)

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Mar. 31, 2022
Revenue Recognition
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) Primary care portfolio $ 272 $ 1,209 $ 889 $ 8,339 Pediatric portfolio ​ ​ 13,590 ​ ​ 3,918 ​ ​ 41,499 ​ ​ 9,752 Consumer Health portfolio ​ ​ 10,337 ​ ​ 8,356 ​ ​ 26,833 ​ ​ 24,059 Consolidated revenue $ 24,199 $ 13,483 $ 69,221 $ 42,150 ​
Schedule of product revenues by geographic location	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) U.S. ​ $ 23,755 ​ $ 12,344 ​ $ 67,408 ​ $ 38,245 International ​ 444 ​ 1,139 ​ 1,813 ​ 3,905 Total net revenue ​ $ 24,199 ​ $ 13,483 ​ $ 69,221 ​ $ 42,150

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Mar. 31, 2022
Inventories
Schedule of Inventory balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ (In thousands) Raw materials $ 1,796 $ 2,269 Work in process ​ ​ 2,222 ​ ​ 3,346 Finished goods ​ 9,873 ​ 10,724 Inventory, net ​ $ 13,891 ​ $ 16,339

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2022
Property and Equipment
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,139 $ 3,070 Leasehold improvements 999 ​ 959 Office equipment, furniture and other 1,120 ​ 1,093 Lab equipment 832 ​ 832 Assets under construction 129 ​ 198 Property and equipment, gross ​ ​ 5,219 ​ ​ 6,152 Less accumulated depreciation and amortization ​ ​ (1,740) ​ ​ (1,012) Property and equipment, net $ 3,479 ​ $ 5,140 ​

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Leases
Schedule of components of lease expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ ​ March 31, ​ March 31, ​ ​ ​ 2022 2021 2022 2021 Statement of Operations Classification ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 316 ​ $ 70 ​ $ 942 ​ $ 195 Operating expenses Short-term lease cost 65 ​ 9 ​ 130 ​ 14 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets 18 ​ 19 ​ 55 ​ 19 Cost of sales Interest on lease liabilities ​ ​ 3 ​ ​ 1 ​ ​ 11 ​ ​ 1 ​ Other (expense), net Total net lease cost $ 402 ​ $ 99 ​ $ 1,138 ​ $ 229 ​
Schedule of balance sheet information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, Balance Sheet Classification ​ ​ 2022 ​ 2021 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ $ 3,561 ​ $ 3,563 Operating lease right-of-use asset Finance lease assets ​ ​ 274 ​ 329 Property and equipment, net, net Total leased assets ​ $ 3,835 ​ $ 3,892 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,203 ​ $ 940 ​ Current portion of operating lease liabilities Finance leases ​ ​ 100 ​ ​ 102 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 2,406 ​ ​ 2,624 ​ Operating lease liabilities, net of current portion Finance leases ​ ​ 106 ​ ​ 180 ​ Debt, net of current portion Total lease liabilities ​ $ 3,815 ​ $ 3,846 ​ ​ ​
Schedule of remaining lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.86 ​ ​ 3.42 ​ Finance lease assets ​ 1.98 ​ ​ 2.72 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 7.44 % ​ 6.62 % Finance lease assets ​ ​ 6.43 % ​ 6.41 % ​
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ March 31, ​ 2022 2021 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 942 ​ $ 195 Operating cash flows from finance leases ​ $ 12 ​ $ 1 Financing cash flows from finance leases ​ $ 76 ​ $ 3 ​
Schedule of maturities of future minimum lease payments, operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2022 (remaining 3 months) ​ $ 357 ​ $ 29 2023 ​ ​ 1,436 ​ ​ 104 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 4,057 ​ ​ 220 Less: Imputed interest ​ ​ (448) ​ ​ (14) Lease liabilities ​ $ 3,609 ​ $ 206
Schedule of maturities of future minimum lease payments, finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2022 (remaining 3 months) ​ $ 357 ​ $ 29 2023 ​ ​ 1,436 ​ ​ 104 2024 ​ ​ 1,379 ​ ​ 87 2025 ​ ​ 749 ​ ​ — 2026 ​ ​ 90 ​ ​ — 2027 ​ ​ 46 ​ ​ — Total lease payments ​ ​ 4,057 ​ ​ 220 Less: Imputed interest ​ ​ (448) ​ ​ (14) Lease liabilities ​ $ 3,609 ​ $ 206

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2022
Goodwill and Other Intangible Assets
Schedule of change in carrying amount of goodwill	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BioPharma Consumer Health Consolidated ​ ​ (In thousands) Balance as of June 30, 2021 ​ $ 57,165 ​ $ 8,637 ​ $ 65,802 Goodwill impairment ​ (19,453) ​ — ​ (19,453) Balance as of September 30, 2021 ​ ​ 37,712 ​ ​ 8,637 ​ ​ 46,349 Goodwill impairment ​ ​ — ​ ​ — ​ ​ — Balance as of December 31, 2021 ​ ​ 37,712 ​ ​ 8,637 ​ ​ 46,349 Goodwill impairment ​ ​ (37,712) ​ — ​ (37,712) Balance as of March 31, 2022 ​ $ — ​ $ 8,637 ​ $ 8,637
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,778) ​ $ (1,468) ​ $ — ​ — Acquired product technology right ​ 45,400 ​ (6,864) ​ (3,224) ​ 35,312 12.21 Acquired technology right ​ ​ 30,200 ​ ​ (1,834) ​ ​ — ​ ​ 28,366 ​ 16.00 Acquired product distribution rights ​ 11,354 ​ (3,204) ​ — ​ 8,150 7.85 Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (630) ​ ​ — ​ ​ — ​ — Acquired trade name ​ ​ 400 ​ ​ (206) ​ ​ (194) ​ ​ — ​ — Acquired customer lists ​ 390 ​ (390) ​ — ​ — — Total ​ $ 94,220 ​ $ (14,906) ​ $ (4,886) ​ $ 74,428 13.21 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,430) ​ $ 1,816 ​ 3.92 Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (178) ​ ​ 452 ​ 0.75 Acquired trade name ​ ​ 400 ​ ​ (56) ​ ​ 344 ​ 1.75 Acquired customer lists ​ ​ 390 ​ ​ (358) ​ ​ 32 ​ 0.01 Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​
Schedule of Indefinite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,778) ​ $ (1,468) ​ $ — ​ — Acquired product technology right ​ 45,400 ​ (6,864) ​ (3,224) ​ 35,312 12.21 Acquired technology right ​ ​ 30,200 ​ ​ (1,834) ​ ​ — ​ ​ 28,366 ​ 16.00 Acquired product distribution rights ​ 11,354 ​ (3,204) ​ — ​ 8,150 7.85 Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ — ​ ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (630) ​ ​ — ​ ​ — ​ — Acquired trade name ​ ​ 400 ​ ​ (206) ​ ​ (194) ​ ​ — ​ — Acquired customer lists ​ 390 ​ (390) ​ — ​ — — Total ​ $ 94,220 ​ $ (14,906) ​ $ (4,886) ​ $ 74,428 13.21 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Gross ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Carrying ​ Accumulated ​ Net Carrying ​ Remaining ​ Amount Amortization Amount Life (in years) ​ ​ (In thousands) Licensed assets ​ $ 3,246 ​ $ (1,430) ​ $ 1,816 ​ 3.92 Acquired product technology right ​ ​ 45,400 ​ ​ (4,160) ​ ​ 41,240 ​ 12.88 Acquired technology right ​ ​ 30,200 ​ ​ (501) ​ ​ 29,699 ​ 16.75 Acquired product distribution rights ​ ​ 11,354 ​ ​ (2,073) ​ ​ 9,281 ​ 8.57 Acquired in-process R&D ​ 2,600 ​ — ​ 2,600 ​ Indefinite-lived Acquired commercial technology ​ ​ 630 ​ ​ (178) ​ ​ 452 ​ 0.75 Acquired trade name ​ ​ 400 ​ ​ (56) ​ ​ 344 ​ 1.75 Acquired customer lists ​ ​ 390 ​ ​ (358) ​ ​ 32 ​ 0.01 Total ​ $ 94,220 ​ $ (8,756) ​ $ 85,464 ​ 13.47 ​ ​
Schedule of future amortization expense	​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2022 (remaining 3 months) ​ $ 1,624 2023 ​ ​ 6,490 2024 ​ ​ 6,477 2025 ​ ​ 6,282 2026 ​ ​ 5,938 2027 ​ ​ 5,908 Thereafter ​ ​ 39,109 Total future amortization expense ​ $ 71,828

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Mar. 31, 2022
Accrued Liabilities
Schedule of Accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Accrued program liabilities ​ $ 12,058 ​ $ 8,689 Accrued product-related fees ​ 1,997 ​ 2,501 Accrued savings offers ​ ​ 17,853 ​ ​ 20,148 Accrued distributor fees ​ ​ 5,303 ​ ​ 2,710 Accrued liabilities for trade partners ​ 2,003 ​ 5,421 Accrued option exercise and milestone fees ​ ​ 3,257 ​ ​ 600 Medicaid liabilities ​ 1,487 ​ 1,714 Return reserve ​ 5,969 ​ 6,367 Other accrued liabilities* ​ 3,543 ​ 3,145 Total accrued liabilities ​ $ 53,470 ​ $ 51,295 *

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Mar. 31, 2022
Long-term Debt
Schedule of long term debt	​ ​ ​ ​ ​ ​ March 31, ​ ​ 2022 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (1,577) Financing leases, maturing through May 2024 ​ ​ 206 Total debt ​ ​ 14,267 Less: current portion ​ ​ (100) Non-current portion of debt ​ $ 14,167
Schedule of future principal payments of long term debt	​ ​ ​ ​ ​ ​ March 31, ​ ​ (In thousands) 2022 ​ $ 100 2023 ​ ​ 5,924 2024 ​ ​ 9,820 Future principal payments ​ ​ 15,844 Less unamortized discount and issuance costs ​ ​ (1,577) Less current portion ​ ​ (100) Non-current portion of debt ​ $ 14,167

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	9 Months Ended
	Mar. 31, 2022
Fair Value Considerations
Schedule of fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at March 31, 2022 ​ Fair Value at March 31, ​ ​ ​ ​ ​ 2022 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 27,613 ​ $ 27,613 ​ $ — ​ $ — Total ​ $ 27,613 $ 27,613 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration $ 371 $ — $ — $ 371 CVR liability ​ 720 ​ — ​ — ​ 720 Total ​ $ 1,091 $ — $ — ​ $ 1,091 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2021 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2021 (Level 1) (Level 2) (Level 3) ​ (In thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 49,649 ​ $ 49,649 ​ $ — ​ $ — Total ​ $ 49,649 $ 49,649 $ — ​ $ — Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent consideration ​ $ 12,057 $ — $ — $ 12,057 CVR liability ​ ​ 1,395 ​ — ​ — ​ 1,395 Total ​ $ 13,452 $ — $ — ​ $ 13,452
Schedule of changes in Level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CVR Contingent ​ ​ Warrant ​ ​ Liability ​ Consideration ​ ​ Liability ​ ​ (In thousands) Balance as of June 30, 2021 $ 1,395 ​ $ 12,057 ​ $ — Included in earnings ​ (675) ​ ​ 579 ​ ​ (211) Purchases, issues, sales and settlements: ​ ​ ​ ​ ​ ​ Issues — ​ — ​ 590 Settlements * — ​ (12,265) ​ (379) Balance as of March 31, 2022 $ 720 ​ $ 371 ​ $ —
Schedule of significant assumptions used in valuation	Significant assumptions used in valuing CVRs were as follows: ​ ​ ​ ​ ​ ​ March 31, ​ 2022 Leveraged Beta 0.79 ​ Market risk premium ​ 6.22 % Risk-free interest rate ​ 2.12 % Discount ​ 19.50 % Company specific discount 10.00 % ​ Significant assumptions used in valuing the warrants were as follows: ​ ​ ​ ​ ​ ​ January 26, ​ 2022 Expected volatility 56.75 % Equivalent term (years) ​ 5.00 ​ Risk-free rate ​ 1.66 % Dividend yield ​ 0.00 %

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Mar. 31, 2022
Equity Incentive Plans
Stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 109,588 ​ $ 14.52 8.07 Forfeited/Cancelled (15,132) ​ ​ 8.03 Expired (10,599) ​ ​ 9.16 Outstanding at March 31, 2022 83,857 ​ $ 16.37 7.79 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at March 31, 2022 55,611 ​ $ 20.51 7.68
Restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 1,955,268 ​ $ 7.83 Granted 295,000 ​ ​ 3.67 Vested (112,787) ​ ​ 8.03 Unvested at March 31, 2022 2,137,481 ​ $ 7.25
Restricted stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2021 78,318 ​ $ 7.20 Granted ​ 150,000 ​ ​ 1.33 Vested (10,908) ​ ​ 6.50 Forfeited ​ (62,922) ​ ​ 7.44 Unvested at March 31, 2022 154,488 ​ $ 1.45
Stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) Cost of sales ​ $ 7 ​ $ 9 ​ $ 24 ​ $ 9 Research and development ​ ​ 73 ​ ​ 3 ​ ​ 467 ​ ​ 3 Selling and marketing ​ ​ 23 ​ ​ 5 ​ ​ 51 ​ ​ 5 General and Administrative ​ 1,167 ​ 1,505 ​ 3,476 ​ 2,468 Total stock-based compensation expense ​ $ 1,270 ​ $ 1,522 ​ $ 4,018 ​ $ 2,485

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Mar. 31, 2022
Warrants
Significant assumptions in valuing the warrants issued	​ ​ ​ ​ ​ ​ ​ March 7, ​ ​ 2022 Valuation method ​ Black-Scholes ​ Expected volatility 54.45 % Equivalent term (years) ​ 4.89 - 5.00 ​ Risk-free rate ​ 1.71 % Dividend yield ​ 0.00 %
Schedule of equity-based warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2021 1,254,952 ​ $ 35.85 2.83 Warrants issued 10,563,769 ​ 0.92 5.37 Warrants expired (124,250) ​ 124.69 — Outstanding March 31, 2022 11,694,471 ​ $ 3.43 4.98

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2022
Net Loss Per Common Share
Antidilutive securities excluded from the computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ 2022 2021 Warrants to purchase common stock - liability classified (Note 16) ​ 24,105 24,105 Warrant to purchase common stock - equity classified (Note 16) ​ 8,664,471 1,257,525 Employee stock options (Note 15) ​ 83,857 136,254 Employee unvested restricted stock (Note 15) ​ 2,137,481 274,635 Employee unvested restricted stock units ​ (Note 15) ​ 154,488 ​ 87,362 Total ​ ​ ​ 11,064,402 1,779,881

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Mar. 31, 2022
Segment Reporting
Segment financial information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ March 31, ​ March 31, ​ 2022 2021 ​ 2022 2021 ​ ​ (In thousands) ​ (In thousands) Consolidated revenue: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 13,862 ​ $ 5,127 ​ $ 42,388 ​ $ 18,091 Consumer Health ​ 10,337 ​ 8,356 ​ 26,833 ​ 24,059 Consolidated revenue ​ $ 24,199 ​ $ 13,483 ​ $ 69,221 ​ $ 42,150 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated net loss: ​ ​ ​ ​ BioPharma ​ $ (52,311) ​ $ (23,570) ​ $ (88,359) ​ $ (34,788) Consumer Health ​ (762) ​ (1,890) ​ (4,113) ​ (4,503) Consolidated net loss ​ $ (53,073) ​ $ (25,460) ​ $ (92,472) ​ $ (39,291) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ June 30, ​ ​ 2022 ​ 2021 ​ ​ (In thousands) Total assets: ​ ​ ​ ​ ​ ​ BioPharma ​ $ 139,127 ​ $ 236,449 Consumer Health ​ 29,699 ​ 29,219 Consolidated assets ​ $ 168,826 ​ $ 265,668

Nature of Business, Financial_2

Nature of Business, Financial Condition, Basis of Presentation - Product Information (Details)	9 Months Ended
	Mar. 31, 2022product
Consumer Health Portfolio | Minimum
Revenue Recognition
Number of products	20

Nature of Business, Financial_3

Nature of Business, Financial Condition, Basis of Presentation - General Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash	$ 27,613	$ 46,790	$ 27,613	$ 46,790	$ 49,901	$ 48,333
Net loss
Net loss	(53,073)	$ (25,460)	(92,472)	(39,291)
Accumulated deficit
Accumulated deficit	$ (270,771)		(270,771)		$ (178,299)
Operating activities
Cash used in operations			$ (21,728)	$ (19,687)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Mar. 31, 2022
Significant Accounting Policies
Goodwill impairment, decrease in net deferred tax liability	$ 100
Income tax benefit	$ (100)	$ (110)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)	Mar. 31, 2022
Accounting Standards Update 2020-04
Recent Accounting Pronouncements
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Mar. 31, 2022
Accounting Standards Update 2020-06
Recent Accounting Pronouncements
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2016-13
Recent Accounting Pronouncements
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Acquisitions - General Informat

Acquisitions - General Information (Details) - USD ($) $ in Thousands	Mar. 19, 2021	Mar. 31, 2021	Mar. 31, 2021
General information
Acquisition related costs		$ 1,537	$ 2,849
Neos Therapeutics, Inc.
Date of acquisition
Business acquisition, effective date of acquisition	Mar. 19, 2021
General information
Business acquisition, equity interest issued or issuable, number of shares (in shares)	5,471,804
Acquisition related costs	$ 2,900
Issuance costs	$ 100

Acquisitions - Considerations (

Acquisitions - Considerations (Details) - Neos Therapeutics, Inc. $ / shares in Units, $ in Thousands	Mar. 19, 2021USD ($)$ / sharesshares
Considerations:
Total shares issued at close (in shares) | shares	5,471,804
Fair value per share of Aytu common stock (in dollars per share) | $ / shares	$ 9.73
Fair value of equity consideration transferred	$ 53,241
Cash	15,383
Estimated fair value of replacement equity awards	432
Total consideration transferred	$ 69,056

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 19, 2021
Recognized amounts of identifiable assets acquired, and liabilities assumed
Goodwill	$ 8,637	$ 46,349	$ 46,349	$ 65,802
Neos Therapeutics, Inc.
Recognized amounts of identifiable assets acquired, and liabilities assumed
Total consideration transferred					$ 69,056
Cash and cash equivalents					15,722
Accounts receivable					24,696
Inventory					10,984
Prepaid expenses and other current assets					2,929
Operating leases right-to-use assets					3,515
Property, plant and equipment					5,519
Intangible assets					56,530
Other long-term assets					149
Accounts payable and accrued expenses					(56,718)
Short-term line of credit					(10,707)
Long-term debt, including current portion					(17,678)
Operating lease liabilities					(3,515)
Other long-term liabilities					(82)
Total identifiable net assets					31,344
Goodwill					$ 37,712

Acquisitions - Identifiable Int

Acquisitions - Identifiable Intangible Assets Acquired - General Information (Details) - Neos Therapeutics, Inc.	9 Months Ended
	Mar. 31, 2022
Minimum
Acquisitions
Estimated useful lives	1 year
Maximum
Acquisitions
Estimated useful lives	17 years

Acquisitions - Identifiable I_2

Acquisitions - Identifiable Intangible Assets Acquired - Tabular Disclosure (Details) - Neos Therapeutics, Inc. $ in Thousands	Mar. 19, 2021USD ($)
Identifiable intangible assets acquired
Indefinite-lived intangible assets acquired	$ 2,600
Total intangible assets acquired	56,530
Developed Technology Right
Identifiable intangible assets acquired
Finite-lived intangible assets acquired	30,200
Developed Products Technology
Identifiable intangible assets acquired
Finite-lived intangible assets acquired	22,700
RXConnect
Identifiable intangible assets acquired
Finite-lived intangible assets acquired	630
Trade Name
Identifiable intangible assets acquired
Finite-lived intangible assets acquired	$ 400

Acquisitions - Unaudited Pro Fo

Acquisitions - Unaudited Pro Forma Results (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Acquisitions
Total revenues, net	$ 69,221	$ 74,582
Net (loss)	$ (92,472)	$ (55,712)

Acquisitions - Asset Acquisitio

Acquisitions - Asset Acquisitions (Details) - Rumpus $ in Millions	Apr. 12, 2021USD ($)
Asset acquisitions
Cash transferred	$ 1.5
Payment of aggregated fees	0.6
Contingent consideration	$ 67.5

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Millions	Mar. 31, 2022	Jun. 30, 2021
Contract with customer liability
Contract with customer liability	$ 0.1	$ 0.2

Revenue Recognition - Revenues

Revenue Recognition - Revenues by Product Portfolio (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)itemproduct	Mar. 31, 2021USD ($)
Revenue Recognition
Revenue from contract with customer	$ 24,199	$ 13,483	$ 69,221	$ 42,150
Gross profit	12,686	(452)	$ 37,441	17,901
Number of product portfolios | item			3
Primary Care Portfolio
Revenue Recognition
Revenue from contract with customer	272	1,209	$ 889	8,339
Pediatric Portfolio
Revenue Recognition
Revenue from contract with customer	13,590	3,918	41,499	9,752
Consumer Health Portfolio
Revenue Recognition
Revenue from contract with customer	$ 10,337	$ 8,356	$ 26,833	$ 24,059
Consumer Health Portfolio | Minimum
Revenue Recognition
Number of products | product			20
Discontinued Non-core Product
Revenue Recognition
Revenue from contract with customer			$ 1,700
Gross profit			$ (600)

Revenue Recognition - Revenue_2

Revenue Recognition - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenue Recognition
Revenue from contract with customer	$ 24,199	$ 13,483	$ 69,221	$ 42,150
U.S.
Revenue Recognition
Revenue from contract with customer	23,755	12,344	67,408	38,245
International
Revenue Recognition
Revenue from contract with customer	$ 444	$ 1,139	$ 1,813	$ 3,905

Inventories - Write-down (Detai

Inventories - Write-down (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Inventory write-down
Inventory write-down		$ 7,000	$ 352	$ 7,227
Impairment expense	$ 45,196	$ 4,286	64,649	$ 4,286
Inventory write-down and impairment	2,000		2,400
Discontinued Non-core Product
Inventory write-down
Impairment expense	$ 2,000		$ 2,000

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Inventory, net
Raw materials	$ 1,796	$ 2,269
Work in process	2,222	3,346
Finished goods	9,873	10,724
Inventory, net	$ 13,891	$ 16,339

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Property, Plant and Equipment
Property and equipment, gross	$ 5,219	$ 6,152
Less accumulated depreciation and amortization	(1,740)	(1,012)
Property and equipment, net	3,479	5,140
Manufacturing Equipment
Property, Plant and Equipment
Property and equipment, gross	2,139	3,070
Leasehold Improvements
Property, Plant and Equipment
Property and equipment, gross	999	959
Office Equipment, Furniture and Other
Property, Plant and Equipment
Property and equipment, gross	1,120	1,093
Lab Equipment
Property, Plant and Equipment
Property and equipment, gross	832	832
Asset under Construction
Property, Plant and Equipment
Property and equipment, gross	$ 129	$ 198

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Depreciation expense
Depreciation expense	$ 500	$ 100	$ 1,300	$ 100
Loss on sale of equipment
Loss on sale of equipment	44		44	(112)
Impairment expense	45,196	4,286	64,649	4,286
Tussionex
Loss on sale of equipment
Impairment expense	$ 200	$ 0	$ 200	$ 0

Leases - General Information (D

Leases - General Information (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)	Oct. 31, 2021USD ($)ft²	Sep. 01, 2021USD ($)ft²	Jun. 30, 2021USD ($)	Mar. 19, 2021USD ($)
Operating leases
Operating lease right-of-use asset	$ 3,561			$ 3,563
Operating lease liabilities	$ 3,609
Operating lease, borrowing rate (as a percent)	18.00%
Finance leases
Lessee, Operating Lease, Existence of Option to Extend [true false]	true
Lessee, Finance Lease, Existence of Option to Extend [true false]	true
Office Space and Manufacturing Facilities, Grand Prairie, Texas
Operating leases
Operating lease right-of-use asset					$ 3,500
Operating lease liabilities					$ 3,500
Operating lease, borrowing rate (as a percent)					6.70%
Finance leases
Finance leases, interest rate (as a percent)					5.90%
Office, Berwyn, Pennsylvania
Operating leases
Area leased | ft²			6,352
Operating lease right-of-use asset			$ 500
Operating lease liabilities			$ 500
Operating lease, borrowing rate (as a percent)			6.25%
Warehouse in Oceanside, California
Operating leases
Area leased | ft²		6,580
Operating lease right-of-use asset		$ 300
Operating lease liabilities		$ 300

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net lease cost
Operating lease cost	$ 316	$ 70	$ 942	$ 195
Short-term lease cost	65	9	130	14
Amortization of leased assets	18	19	55	19
Interest on lease liabilities	3	1	11	1
Total net lease cost	$ 402	$ 99	$ 1,138	$ 229

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 3,561	$ 3,563
Finance lease assets	$ 274	$ 329
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 3,835	$ 3,892
Current portion of operating lease liabilities	1,203	940
Finance leases, current	$ 100	$ 102
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 2,406	$ 2,624
Finance leases, long-term	$ 106	$ 180
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Debt, net of current portion	Debt, net of current portion
Total lease liabilities	$ 3,815	$ 3,846

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Mar. 31, 2022	Jun. 30, 2021
Leases
Operating lease assets, weighted-average remaining lease term (years)	2 years 10 months 9 days	3 years 5 months 1 day
Finance lease assets, weighted-average remaining lease term (years)	1 year 11 months 23 days	2 years 8 months 19 days
Operating lease assets, weighted-average discount rate	7.44%	6.62%
Finance lease assets, weighted-average discount rate	6.43%	6.41%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases
Operating cash flows from operating leases	$ 942	$ 195
Operating cash flows from finance leases	12	1
Financing cash flows from finance leases	$ 76	$ 3

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating leases
2022 (remaining 3 months)	$ 357
2023	1,436
2024	1,379
2025	749
2026	90
2027	46
Total lease payments	$ 4,057

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating leases
Total lease payments	$ 4,057
Less: Imputed interest	(448)
Lease liabilities	$ 3,609

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2022USD ($)
Finance leases
2022 (remaining 3 months)	$ 29
2023	104
2024	87
Total lease payments	$ 220

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) $ in Thousands	Mar. 31, 2022USD ($)
Finance leases
Total lease payments	$ 220
Less: Imputed interest	(14)
Lease liabilities	$ 206

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Goodwill Impairment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Impairment
Goodwill impairment	$ 37,712,000	$ 19,453,000
Goodwill	8,637,000	46,349,000	$ 8,637,000	$ 46,349,000	$ 65,802,000
BioPharma
Impairment
Goodwill impairment	37,712,000	19,453,000	37,700,000
Goodwill		37,712,000		37,712,000	57,165,000
Consumer Health
Impairment
Goodwill impairment	0
Goodwill	8,637,000	8,637,000	8,637,000	$ 8,637,000	$ 8,637,000
Reporting unit, fair value		5,900,000
Reporting unit, carrying value	$ (2,200,000)	$ 500,000	$ (2,200,000)

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2022
Goodwill
Goodwill, beginning balance	$ 46,349,000	$ 65,802,000	$ 65,802,000
Goodwill impairment	(37,712,000)	(19,453,000)
Goodwill, ending balance	8,637,000	46,349,000	8,637,000
BioPharma
Goodwill
Goodwill, beginning balance	37,712,000	57,165,000	57,165,000
Goodwill impairment	(37,712,000)	(19,453,000)	(37,700,000)
Goodwill, ending balance		37,712,000
Consumer Health
Goodwill
Goodwill, beginning balance	8,637,000	8,637,000	8,637,000
Goodwill impairment	0
Goodwill, ending balance	$ 8,637,000	$ 8,637,000	$ 8,637,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Finite-lived intangible assets
Accumulated amortization	$ (14,906)	$ (8,756)
Impairment	(4,886)
Finite-lived intangible assets, net	71,828
Licensed assets
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	3,246	3,246
Accumulated amortization	(1,778)	(1,430)
Impairment	(1,468)
Finite-lived intangible assets, net		1,816
Product Technology Right
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	45,400	45,400
Accumulated amortization	(6,864)	(4,160)
Impairment	(3,224)
Finite-lived intangible assets, net	35,312	41,240
Developed Technology Right
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Accumulated amortization	(1,834)	(501)
Finite-lived intangible assets, net	28,366	29,699
Product distribution rights
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	11,354	11,354
Accumulated amortization	(3,204)	(2,073)
Finite-lived intangible assets, net	8,150	9,281
Commercial technology
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	630	630
Accumulated amortization	(630)	(178)
Finite-lived intangible assets, net		452
Trade Name
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	400	400
Accumulated amortization	(206)	(56)
Impairment	(194)
Finite-lived intangible assets, net		344
Customer lists
Finite-lived intangible assets
Finite-lived intangible assets, gross carrying amount	390	390
Accumulated amortization	$ (390)	(358)
Finite-lived intangible assets, net		$ 32

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life	13 years 2 months 15 days	13 years 5 months 19 days
Licensed assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life		3 years 11 months 1 day
Product Technology Right
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life	12 years 2 months 15 days	12 years 10 months 17 days
Developed Technology Right
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life	16 years	16 years 9 months
Product distribution rights
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life	7 years 10 months 6 days	8 years 6 months 25 days
Commercial technology
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life		9 months
Trade Name
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life		1 year 9 months
Customer lists
Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted-average remaining life		3 days

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Intangible assets
Indefinite-lived intangible assets	$ 2,600	$ 2,600
Intangible assets, gross carrying amount	94,220	94,220
Accumulated amortization	(14,906)	(8,756)
Impairment	(4,886)
Intangible assets, net carrying amount	$ 74,428	$ 85,464

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2022USD ($)
Estimated future amortization expense
2022 (remaining 3 months)	$ 1,624
2023	6,490
2024	6,477
2025	6,282
2026	5,938
2027	5,908
Thereafter	39,109
Finite-lived intangible assets, net	$ 71,828

Goodwill and Other Intangible_9

Goodwill and Other Intangible Assets - Renewal Options (Details)	9 Months Ended
	Mar. 31, 2022
Minimum
Finite-lived intangible assets
Finite-lived intangible asset, period before next renewal or extension (years)	1 year
Maximum
Finite-lived intangible assets
Finite-lived intangible asset, period before next renewal or extension (years)	20 years

Goodwill and Other Intangibl_10

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total amortization expense	$ 2,000	$ 1,700	$ 6,100	$ 4,900
Amortization of intangible assets	1,061	1,585	3,214	4,754
Impairment	4,900	$ 4,300	4,900	$ 4,300
Trade Name
Finite-Lived Intangible Assets [Line Items]
Impairment	200		200
AcipHex
Finite-Lived Intangible Assets [Line Items]
Impairment	2,600		2,600
ZolpiMist
Finite-Lived Intangible Assets [Line Items]
Impairment	1,400		1,400
Tussionex
Finite-Lived Intangible Assets [Line Items]
Impairment	500		500
Cefaclor
Finite-Lived Intangible Assets [Line Items]
Impairment	$ 200		$ 200

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Accrued Liabilities
Accrued program liabilities	$ 12,058	$ 8,689
Accrued product-related fees	1,997	2,501
Accrued savings offers	17,853	20,148
Accrued distributor fees	5,303	2,710
Accrued liabilities for trade partners	2,003	5,421
Accrued option exercise and milestone fees	3,257	600
Medicaid liabilities	1,487	1,714
Return reserve	5,969	6,367
Other accrued liabilities	3,543	3,145
Total accrued liabilities	$ 53,470	$ 51,295

Line of Credit (Details)

Line of Credit (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2022	Jan. 26, 2022	Jan. 25, 2022	Jun. 30, 2021
Debt
Period of notice required before prepaying the debt instrument			5 days
Interest expense		$ 400,000
Legal and other fees			$ 100,000
Aggregate borrowing capacity				$ 3,500,000	$ 1,000,000
Amortization of deferred financing costs		100,000	400,000
Other Noncurrent Assets [Member]
Debt
Unamortized debt issuance expense		100,000	$ 100,000
Revolving Credit Facility [Member]
Debt
Maximum borrowing capacity				$ 12,500,000	$ 25,000,000
Event Occurs on or before January 26, 2023 [Member]
Debt
Commitment fee percentage			2.00%
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt
Commitment fee percentage			1.00%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt
Commitment fee percentage			0.50%
Neos Therapeutics, Inc. | Loan Agreement
Debt
Maximum borrowing capacity	$ 25,000,000
Maximum borrowing capacity portion available for short-term swingline loans	$ 2,500,000
Percentage of eligible accounts receivable against which short-term swingline loans may be made	85.00%
Unused capacity commitment fee percentage	0.50%
Interest expense	$ 28,000
Outstanding amount		$ 3,400,000	$ 3,400,000			$ 7,900,000
Neos Therapeutics, Inc. | Loan Agreement | London Interbank Offered Rate (LIBOR)
Debt
Basis spread on variable rate	4.50%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 07, 2022	Jan. 26, 2022	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 29, 2022	Jun. 29, 2021	Mar. 20, 2021
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt			$ 169	$ 169	$ (258)
Debt Instrument, Interest Payment Term		18 months
Debt Instrument, Interest Payment Extension Term		6 months
Interest Only Period Further Extension Term		6 months
Debt Instrument, Term of Trailing Months Revenue		12 months
Debt Instrument Prepayment Fee Percentage		3.00%
Long-term, final payment fee		$ 600	$ 638	$ 638
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.21	$ 0.0001	$ 0.0001			$ 1.21
Warrants and Rights Outstanding		$ 600	$ 400	$ 400
Loan Processing Fee				$ 400
Debt Instrument, Interest Rate, Effective Percentage			15.37%	15.37%
Interest Expense, Debt			$ 400
Adjustments to Additional Paid in Capital, Warrant Issued			379	$ 379
Avenue Capital Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.21	$ 1.21
Warrants and Rights Outstanding		$ 600
Share Price	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	867,769
Adjustments to Additional Paid in Capital, Warrant Issued	$ 400
Minimum | Avenue Capital Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.21
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage		2.00%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage		1.00%
Deerfield Facility
Debt Instrument [Line Items]
Carrying amount of the remaining outstanding debt					$ 16,600
Gain (loss) on extinguishment of debt			$ 200
Deerfield Facility | Neos Therapeutics, Inc.
Debt Instrument [Line Items]
Fair value of the remaining outstanding debt								$ 17,400
Unamortized premium								$ 800
Interest expense				$ 800
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)		3.25%
Debt instrument, basis spread on variable rate (as a percent)		7.40%
Face amount		$ 15,000

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 26, 2022	Jun. 30, 2021
Line of Credit
Long-term debt, due on January 26, 2025	$ 15,000
Long-term, final payment fee	638	$ 600
Unamortized discount	(1,577)
Financing leases, maturing through May 2024	206
Total debt	14,267
Less current portion	(100)		$ (16,668)
Non-current portion of debt	$ 14,167		$ 180

Long-term Debt - Long-term Debt

Long-term Debt - Long-term Debt Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Line of Credit
2022	$ 100
2023	5,924
2024	9,820
Future principal payments	15,844
Less unamortized discount	(1,577)
Less current portion	(100)	$ (16,668)
Long-term Debt and Lease Obligation	$ 14,167	$ 180

Fair Value Considerations - Fin

Fair Value Considerations - Financial Liabilities, Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Assets:
Cash and cash equivalents	$ 27,613	$ 49,649
Total	27,613	49,649
Liabilities:
Contingent consideration	371	12,057
CVR liability	720	1,395
Total	1,091	13,452
Level 1
Assets:
Cash and cash equivalents	27,613	49,649
Total	27,613	49,649
Level 3
Liabilities:
Contingent consideration	371	12,057
CVR liability	720	1,395
Total	$ 1,091	$ 13,452

Fair Value Considerations - Con

Fair Value Considerations - Contingent Consideration (Details) $ in Thousands	Jul. 01, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	Feb. 14, 2020USD ($)
Fair Value Considerations
Payment for contingent consideration liability			$ 700	$ 500	$ 1,700
Accretion expense		$ 23	15	100	300
Contingent Consideration Liability Derecognized		9,100		9,100
Gain (loss) from contingent consideration		1,257	$ 631	761	$ (2,680)
Tris License Agreement | Other Current Liabilities
Fair Value Considerations
Estimated Litigation Liability		7,600		7,600
Tuzistra XR
Fair Value Considerations
Contingent Consideration Liability Derecognized		8,500		8,500
Gain From Derecognition Of Contingent Consideration Liability, Deferred		900		900
ZolpiMist | Manga License Agreement
Fair Value Considerations
Gain (loss) from contingent consideration				600
ZolpiMist | Manga License Agreement | Other Current Liabilities
Fair Value Considerations
Estimated Litigation Liability		50		50
Innovus
Fair Value Considerations
Contingent consideration		300		300		$ 300	$ 200
Innovus | University of Iowa Research Foundation
Fair Value Considerations
Contingent consideration		100		100		$ 100
Milestone payments made	$ 50
License agreement milestone payment payable		50		50
Total milestone payments		$ 200		$ 200
Innovus | Discount
Fair Value Considerations
Discounted value of future contingent payment							0.30
Innovus | Discount | University of Iowa Research Foundation
Fair Value Considerations
Discounted value of future contingent payment		0.26		0.26

Fair Value Considerations - C_2

Fair Value Considerations - Contingent Value Rights (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 20, 2021	Mar. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jan. 26, 2022	Jun. 30, 2021	Jun. 29, 2021
Fair Value Considerations
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.0001		$ 0.0001		$ 1.21		$ 1.21
Warrants and Rights Outstanding			$ 400		$ 400		$ 600
Fair Value Adjustment of Warrants			(211)		(211)
Innovus
Fair Value Considerations
Additional maximum contingent consideration			16,000		$ 16,000
Maximum shares to be issued to settle CVR shares					470,000
Number of shares issued to contingent value rights share holders	103,190	123,820
Contingent value rights amount		$ 2,000
First milestone			24,000		$ 24,000
Gain (loss) from change in fair value of CVR			700	$ (100)	700	$ 1,000
CVR liability			$ 700		700			$ 1,400
Innovus | Milestone 2021
Fair Value Considerations
Contingent value rights amount	$ 1,000
First milestone	40,000
Milestone not met during the year					1,000
Innovus | Milestone 2020
Fair Value Considerations
Contingent value rights amount	1,000
First milestone	$ 30,000
Milestone not met during the year					$ 1,000

Fair Value Considerations - Uno

Fair Value Considerations - Unobservable Inputs Reconciliation, Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Jan. 26, 2022
Summary of Level 3 input changes
Contingent Consideration Liability Derecognized	$ 9,100
Warrants and Rights Outstanding	400	$ 600
Contingent Value Rights
Summary of Level 3 input changes
Beginning balance	1,395
Included in earnings	(675)
Ending balance	720
Contingent Consideration
Summary of Level 3 input changes
Beginning balance	12,057
Included in earnings	579
Settlements	(12,265)
Ending balance	371
Warrant Liability
Summary of Level 3 input changes
Included in earnings	(211)
Issues	590
Settlements	$ (379)

Fair Value Considerations - Val

Fair Value Considerations - Valuation Assumptions - CVRs (Details)	Mar. 31, 2022
Leveraged Beta
Significant assumptions
Contingent value rights, measurement input	0.79
Market risk premium
Significant assumptions
Contingent value rights, measurement input	6.22
Risk-free rate
Significant assumptions
Contingent value rights, measurement input	2.12
Discount
Significant assumptions
Contingent value rights, measurement input	19.50
Company specific discount
Significant assumptions
Contingent value rights, measurement input	10

Fair Value Considerations - V_2

Fair Value Considerations - Valuation Assumptions - Warrant Liability (Details)	Mar. 07, 2022	Jan. 26, 2022
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	54.45	56.75
Equivalent term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		5
Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.71	1.66
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0

Commitments and Contingencies (

Commitments and Contingencies (Details)

Jul. 01, 2021USD ($)

Jun. 21, 2021USD ($)

Apr. 12, 2021USD ($)

May 29, 2020USD ($)

Aug. 31, 2021USD ($)

Jan. 31, 2020USD ($)

Mar. 31, 2022USD ($)

Dec. 07, 2021USD ($)

Jul. 31, 2021USD ($)

Jun. 30, 2021USD ($)

Jan. 31, 2021USD ($)

Feb. 14, 2020USD ($)

Nov. 01, 2019USD ($)

Feb. 28, 2015USD ($)

Rumpus

Commitments and Contingencies

Up-front fee

$ 1,500,000

Payment of aggregated fees

600,000

Contingent consideration

67,500,000

Karbinal Agreement

Commitments and Contingencies

Supply and distribution commitment, period (in Years)

20 years

Percentage of net sales on royalty

23.50%

Maximum yearly make-whole payment

$ 2,100,000

Tris Pharma, Inc.

Commitments and Contingencies

Minimum sales per year

70,000

Tris Pharma, Inc. | Karbinal Agreement

Commitments and Contingencies

Minimum sales per year

70,000

Make-whole payment per unit for sales under minimum

$ 30

Maximum milestone obligations

$ 3,000,000

First milestone, minimum net revenues

$ 40,000,000

Innovus

Commitments and Contingencies

Contingent consideration

300,000

$ 300,000

$ 200,000

Innovus | University of Iowa Research Foundation

Commitments and Contingencies

Total milestone payments

200,000

Contingent consideration

100,000

$ 100,000

Milestone payment payable

50,000

Milestone payments made

$ 50,000

Novalere | Innovus

Commitments and Contingencies

Number of Payments

5

Total milestone payments

$ 500,000

Contingent consideration

$ 300,000

First Pediatric Portfolio Fixed Obligation

Commitments and Contingencies

Monthly payment

$ 86,400

Balloon payment

$ 15,000,000

Repayments Of Fixed Obligation

$ 15,000,000

Second Pediatric Portfolio Fixed Obligation

Commitments and Contingencies

Monthly payment

$ 100,000

Payments For Fixed Obligations To Investor

$ 2,800,000

$ 210,767

Repayments Of Fixed Obligation

3,000,000

Rumpus Earn Out Payments

Commitments and Contingencies

Annual Maintenance Fee Payable

$ 2,500,000

Over Next Six Quarters Commencing September 30, 2021 | Second Pediatric Portfolio Fixed Obligation

Commitments and Contingencies

Repayments Of Fixed Obligation

$ 500,000

In-process R&D | Maximum | Rumpus

Commitments and Contingencies

Contingent consideration

67,500,000

In-process R&D | Denovo Biopharma L L C | Rumpus

Commitments and Contingencies

Contingent consideration

101,700,000

Annual Maintenance Fee Payable

25,000

License Option Fee Payable

600,000

In-process R&D | Johns Hopkins University | Rumpus

Commitments and Contingencies

Contingent consideration

1,600,000

Minimum annual royalties

$ 5,000

Percentage of revenues on royalty payments

3.00%

In-process R&D | Beginning 2022 | Johns Hopkins University | Rumpus

Commitments and Contingencies

Minimum annual royalties

$ 20,000

Capital Structure - Common and

Capital Structure - Common and Preferred Stock (Details) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Common stock
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares outstanding	33,355,935	27,490,412
Preferred stock
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	0	0

Capital Structure - Restricted

Capital Structure - Restricted Stock (Details) - shares	Mar. 31, 2022	Jun. 30, 2021
Equity Incentive Plan
Common stock, shares outstanding	33,355,935	27,490,412
Restricted Stock
Equity Incentive Plan
Common stock, shares outstanding	2,241,089

Capital Structure - Stock Offer

Capital Structure - Stock Offerings (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Sep. 28, 2021	Jun. 04, 2021	Jun. 08, 2020
Capital Structure
Issuance of common stock, net of cash issuance costs	$ 7,034	$ 11,659	$ 29,488
Offering costs		782	$ 4,430
Shelf Registration 2020
Capital Structure
Shelf registration, amount authorized						$ 100,000
Shelf registration remaining amount available for sale	43,000	$ 43,000
At-the-market Offering | Cantor Fitzgerald & Co
Capital Structure
Sales agreement, amount authorized for issuance					$ 30,000
Issuance of common stock, net of cash issuance costs (in shares)		2,430,784
Issuance of common stock, net of cash issuance costs		$ 5,100
Offering costs		200
Shelf registration remaining amount available for sale	12,200	12,200
Shelf Registration 2021
Capital Structure
Shelf registration, amount authorized				$ 100,000
Shelf registration remaining amount available for sale	$ 92,400	$ 92,400

Capital Structure - Underwritin

Capital Structure - Underwriting Agreement (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 07, 2022	Mar. 31, 2022	Jan. 26, 2022	Jun. 29, 2021
Capital Structure
Exercise price of warrants (in dollars per share)		$ 0.0001	$ 1.21	$ 1.21
Fair value of waarrants		$ 0.4	$ 0.6
Underwriting Agreement
Capital Structure
Issuance of common stock, net of cash issuance costs (in shares)	3,030,000
Exercisable term of warrants	6 months
Warrants outstanding term	5 years
Underwriting Agreement | Pre Funded Warrants
Capital Structure
Number of warrants issued to purchase shares (in shares)	3,030,000
Underwriting Agreement | March 2022 Offering
Capital Structure
Proceeds from issuance of warrants	$ 7.6
Other cost of warrants	0.8
Fair value of waarrants	$ 6.3
Underwriting Agreement | March 2022 Offering | Maximum
Capital Structure
Number of warrants issued to purchase shares (in shares)	6,666,000
Underwriting Agreement | March 2022 Offering | Pre Funded Warrants
Capital Structure
Number of warrant to purchase each shares	1.1
Exercise price of warrants (in dollars per share)	$ 0.0001
Underwriting Agreement | March 2022 Offering | Common Warrants
Capital Structure
Exercise price of warrants (in dollars per share)	$ 1.30
Exercisable term of warrants	6 months
Warrants outstanding term	5 years
Underwriting Agreement | March 2022 Offering | Common Warrants | Maximum
Capital Structure
Number of warrants issued to purchase shares (in shares)	6,666,000

Capital Structure - Avenue Capi

Capital Structure - Avenue Capital Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 07, 2022	Mar. 31, 2022	Mar. 31, 2022	Jan. 26, 2022	Jun. 29, 2021
Capital Structure
Exercise price of warrants (in dollars per share)		$ 0.0001	$ 0.0001	$ 1.21	$ 1.21
Fair value of warrants as additional paid in capital		$ 379	$ 379
Avenue Capital Warrants
Capital Structure
Exercise price of warrants (in dollars per share)	$ 1.21			$ 1.21
Number of warrants issued to purchase shares (in shares)	867,769
Share price	$ 1.25
Fair value of warrants as additional paid in capital	$ 400

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - shares	Apr. 19, 2021	Mar. 31, 2022	Jun. 30, 2021	Mar. 19, 2021	Feb. 13, 2020	Jul. 31, 2017
Equity Incentive Plan
Number of options outstanding (in shares)		83,857	109,588
Restricted Stock Units
Equity Incentive Plan
Unvested units outstanding (in shares)		154,488	78,318
Aytu 2015 Plan
Equity Incentive Plan
Number of shares authorized (in shares)					5,000,000	3,000,000
Number of shares available for grant (in shares)		2,401,186
Aytu 2015 Plan | Share-based Payment Arrangement, Option
Equity Incentive Plan
Term of award		10 years
Aytu 2015 Plan | Share-based Payment Arrangement, Option | Minimum
Equity Incentive Plan
Vesting period		3 years
Aytu 2015 Plan | Share-based Payment Arrangement, Option | Maximum
Equity Incentive Plan
Vesting period		4 years
Aytu 2015 Plan | Restricted Stock
Equity Incentive Plan
Unvested units outstanding (in shares)		2,137,481	1,955,268
Aytu 2015 Plan | Restricted Stock | Minimum
Equity Incentive Plan
Vesting period		4 years
Aytu 2015 Plan | Restricted Stock | Maximum
Equity Incentive Plan
Vesting period		10 years
Aytu 2015 Plan | Restricted Stock Units
Equity Incentive Plan
Vesting period		4 years
Neos 2015 Plan
Equity Incentive Plan
Number of options outstanding (in shares)				69,721
Registered shares of common stock (in shares)	105,449
Number of shares available for grant (in shares)		43,151
Neos 2015 Plan | Share-based Payment Arrangement, Option
Equity Incentive Plan
Term of award		10 years
Neos 2015 Plan | Share-based Payment Arrangement, Option | Minimum
Equity Incentive Plan
Vesting period		1 year
Neos 2015 Plan | Share-based Payment Arrangement, Option | Maximum
Equity Incentive Plan
Vesting period		4 years
Neos 2015 Plan | Restricted Stock Units
Equity Incentive Plan
Unvested units outstanding (in shares)				35,728

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Number of Options
Number of options outstanding, beginning balance (in shares)	109,588
Forfeited/cancelled (in shares)	(15,132)
Expired (in shares)	(10,599)
Number of options outstanding, ending balance (in shares)	83,857	109,588
Weighted Average Exercise Price
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 14.52
Forfeited/cancelled (in dollars per share)	8.03
Expired (in dollars per share)	9.16
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 16.37	$ 14.52
Additional information
Outstanding, weighted average remaining contractual life (Year)	7 years 9 months 14 days	8 years 25 days
Number of options exercisable	55,611
Weighted average exercise price exercisable (in dollars per share)	$ 20.51
Weighted average remaining contractual life in years exercisable	7 years 8 months 4 days

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - General Information (Details) - Restricted Stock - Aytu 2015 Plan - $ / shares	Aug. 02, 2021	Mar. 31, 2022
Equity Incentive Plan
Granted (in shares)		295,000
Granted, weighted average grant date fair value (in dollars per share)		$ 3.67
Management
Equity Incentive Plan
Granted (in shares)	295,000
Management | Minimum
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		2.65
Management | Maximum
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		$ 4.02
Management | Tranche One
Equity Incentive Plan
Vesting percentage	33.33%
Management | Tranche Two
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Three
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Four
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Five
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Six
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Seven
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Eight
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Nine
Equity Incentive Plan
Vesting percentage	8.33%

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock - Activity (Details) - Restricted Stock - Aytu 2015 Plan	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Unvested outstanding, beginning balance (in shares) | shares	1,955,268
Granted (in shares) | shares	295,000
Vested (in shares) | shares	(112,787)
Unvested outstanding, ending balance (in shares) | shares	2,137,481
Weighted Average Grant Date Fair Value
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 7.83
Granted (in dollars per share) | $ / shares	3.67
Vested (in dollars per share) | $ / shares	8.03
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 7.25

Equity Incentive Plans - Rest_3

Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock - Non-plan - $ / shares	Jan. 17, 2022	Mar. 31, 2022
Equity Incentive Plan
Unvested units outstanding (in shares)		158
Management
Equity Incentive Plan
Granted (in shares)	100,000
Granted, weighted average grant date fair value (in dollars per share)	$ 1.35
Management | Tranche One
Equity Incentive Plan
Vesting percentage	33.33%
Management | Tranche Two
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Three
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Four
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Five
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Six
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Seven
Equity Incentive Plan
Vesting percentage	8.33%
Management | Tranche Eight
Equity Incentive Plan
Vesting percentage	8.33%

Equity Incentive Plans - Rest_4

Equity Incentive Plans - Restricted Stock Unit - General Information (Details) - Restricted Stock Units - $ / shares	Dec. 01, 2021	Mar. 31, 2022
Equity Incentive Plan
Granted (in shares)		150,000
Granted, weighted average grant date fair value (in dollars per share)		$ 1.33
Aytu 2015 Plan | Management
Equity Incentive Plan
Granted (in shares)	150,000
Aytu 2015 Plan | Management | Minimum
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		1.08
Aytu 2015 Plan | Management | Maximum
Equity Incentive Plan
Granted, weighted average grant date fair value (in dollars per share)		$ 1.86
Aytu 2015 Plan | Management | Tranche One
Equity Incentive Plan
Vesting percentage	33.33%
Aytu 2015 Plan | Management | Tranche Two
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Three
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Four
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Five
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Six
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Seven
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Eight
Equity Incentive Plan
Vesting percentage	8.33%
Aytu 2015 Plan | Management | Tranche Nine
Equity Incentive Plan
Vesting percentage	8.33%

Equity Incentive Plans - Rest_5

Equity Incentive Plans - Restricted Stock Unit - Activity (Details) - Restricted Stock Units	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Unvested outstanding, beginning balance (in shares) | shares	78,318
Granted (in shares) | shares	150,000
Vested (in shares) | shares	(10,908)
Forfeited (in shares) | shares	(62,922)
Unvested outstanding, ending balance (in shares) | shares	154,488
Weighted Average Grant Date Fair Value
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 7.20
Granted (in dollars per share) | $ / shares	1.33
Vested | $ / shares	6.50
Forfeited (in dollars per share) | $ / shares	7.44
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 1.45

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	9 Months Ended
	Mar. 31, 2022USD ($)
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.2
Share-based Payment Arrangement, Option
Unrecognized compensation costs
Unrecognized compensation costs, period for recognition	1 year 9 months 18 days
Restricted Stock | Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 10.8
Unrecognized compensation costs, period for recognition	2 years 10 months 24 days
Restricted Stock | Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 1
Unrecognized compensation costs, period for recognition	4 years 1 month 6 days
Restricted Stock Units
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.2
Unrecognized compensation costs, period for recognition	2 years 9 months 18 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Stock-based compensation expense
Total share-based compensation expense	$ 1,270	$ 1,522	$ 4,018	$ 2,485
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense	7	9	24	9
Research and development
Stock-based compensation expense
Total share-based compensation expense	73	3	467	3
Selling and Marketing
Stock-based compensation expense
Total share-based compensation expense	23	5	51	5
General and Administrative
Stock-based compensation expense
Total share-based compensation expense	$ 1,167	$ 1,505	$ 3,476	$ 2,468

Warrants - General Information

Warrants - General Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 07, 2022	Jul. 01, 2020	Jul. 31, 2021	Mar. 31, 2022	Mar. 31, 2022	Jan. 26, 2022	Jun. 30, 2021	Jun. 29, 2021
Warrants
Exercise price of warrants (in dollars per share)				$ 0.0001	$ 0.0001	$ 1.21		$ 1.21
Warrants outstanding				$ 400	$ 400	$ 600
Fair value of warrants as additional paid in capital				$ 379	$ 379
Equity Warrants
Warrants
Warrants expired (in shares)					124,250
Warrants expired (in dollars per share)					$ 124.69
Outstanding warrants (in shares)				11,694,471	11,694,471		1,254,952
Exercise price of warrants (in dollars per share)				$ 3.43	$ 3.43		$ 35.85
Class of Warrant or Right, Issued During Period (in shares)					10,563,769
Exercise price of warrants (in dollars per share)					$ 0.92
Avenue Capital Warrants
Warrants
Share price	$ 1.25
Number of warrants issued to purchase shares (in shares)	867,769
Exercise price of warrants (in dollars per share)	$ 1.21					$ 1.21
Warrants outstanding						$ 600
Fair value of warrants as additional paid in capital	$ 400
Placement Agent Warrants
Warrants
Warrants expired (in shares)		92,302
Placement Agent Warrants | Weighted Average
Warrants
Warrants expired (in dollars per share)		$ 15.99
Other Warrants Expired
Warrants
Warrants expired (in shares)			31,925
Other Warrants Expired | Weighted Average
Warrants
Warrants expired (in dollars per share)			$ 483.75
Liability Warrants
Warrants
Outstanding warrants (in shares)				24,105	24,105
Exercise price of warrants (in dollars per share)				$ 720	$ 720
Underwriting Agreement
Warrants
Issuance of common stock	3,030,000
Exercisable term of warrants	6 months
Warrants and Rights Outstanding, Term (Year)	5 years
Underwriting Agreement | March 2022 Offering
Warrants
Warrants outstanding	$ 6,300
Underwriting Agreement | Pre-Funded Warrants
Warrants
Number of warrants issued to purchase shares (in shares)	3,030,000
Underwriting Agreement | Pre-Funded Warrants | March 2022 Offering
Warrants
Number of warrant to purchase each shares	1.1
Exercise price of warrants (in dollars per share)	$ 0.0001
Underwriting Agreement | Common Warrants | March 2022 Offering
Warrants
Exercisable term of warrants	6 months
Exercise price of warrants (in dollars per share)	$ 1.30
Warrants and Rights Outstanding, Term (Year)	5 years

Warrants - Significant Assumpti

Warrants - Significant Assumptions Used (Details)	Mar. 07, 2022Y	Jan. 26, 2022
Expected volatility
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input	54.45	56.75
Equivalent term (years)
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input		5
Equivalent term (years) | Minimum
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.89
Equivalent term (years) | Maximum
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input	5
Risk-free rate
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.71	1.66
Dividend yield
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0

Warrants - Equity-based Warrant

Warrants - Equity-based Warrants Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Warrants
Outstanding, exercise price (in dollars per share)	$ 0.0001
Equity Warrants
Warrants
Outstanding, number of warrants (in shares)	1,254,952
Warrants issued (in shares)	10,563,769
Warrants expired (in shares)	(124,250)
Outstanding, number of warrants (in shares)	11,694,471	1,254,952
Outstanding, exercise price (in dollars per share)	$ 35.85
Warrants issued (in dollars per share)	0.92
Warrants expired (in dollars per share)	124.69
Outstanding, exercise price (in dollars per share)	$ 3.43	$ 35.85
Outstanding, weighted average remaining contractual life	4 years 11 months 23 days	2 years 9 months 29 days
Warrants issued, weighted average remaining contractual life	5 years 4 months 13 days

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - $ / shares	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 26, 2022	Jun. 29, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	11,064,402	1,779,881
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001		$ 1.21	$ 1.21
Pre-Funded Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	3,030,000
Liability Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	24,105	24,105
Equity Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	8,664,471	1,257,525
Share-based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	83,857	136,254
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	2,137,481	274,635
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities	154,488	87,362

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2020	Oct. 31, 2017	Feb. 29, 2016
Cedars-Sinai Medical Center
License agreement term	10 years
License fee	$ 0.3
Patent prosecution fees	$ 0.1
License Agreement 2014 | Maximum | Neos Therapeutics, Inc.
Lump sum non-refundable license fee			$ 1
License Agreement 2017 | Maximum | Neos Therapeutics, Inc.
Lump sum non-refundable license fee		$ 1

Segment Reporting - General Inf

Segment Reporting - General Information (Details) - segment	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting
Number of reportable segments	2	2	2	2

Segment Reporting - Consolidate

Segment Reporting - Consolidated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting
Revenue from contract with customer	$ 24,199	$ 13,483	$ 69,221	$ 42,150
BioPharma
Segment Reporting
Revenue from contract with customer	13,862	5,127	42,388	18,091
Consumer Health
Segment Reporting
Revenue from contract with customer	$ 10,337	$ 8,356	$ 26,833	$ 24,059

Segment Reporting - Consolida_2

Segment Reporting - Consolidated Net Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting
Net loss	$ (53,073)	$ (25,460)	$ (92,472)	$ (39,291)
BioPharma
Segment Reporting
Net loss	(52,311)	(23,570)	(88,359)	(34,788)
Consumer Health
Segment Reporting
Net loss	$ (762)	$ (1,890)	$ (4,113)	$ (4,503)

Segment Reporting - Total Asset

Segment Reporting - Total Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Segment Reporting
Assets	$ 168,826	$ 265,668
BioPharma
Segment Reporting
Assets	139,127	236,449
Consumer Health
Segment Reporting
Assets	$ 29,699	$ 29,219

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands	May 12, 2022USD ($)payment	Apr. 19, 2022$ / sharesshares	May 31, 2022USD ($)shares	Apr. 14, 2022USD ($)	Mar. 31, 2022$ / shares	Jan. 26, 2022$ / shares	Dec. 07, 2021USD ($)	Jun. 29, 2021$ / shares
Subsequent Events
Exercise price of warrants (in dollars per share) | $ / shares					$ 0.0001	$ 1.21		$ 1.21
Rumpus Earn Out Payments
Subsequent Events
Annual maintenance fee payable							$ 2,500
Subsequent Event
Subsequent Events
Exercise price of warrants (in dollars per share) | $ / shares		$ 0.0001
Issuance of common stock, net of cash issuance costs (in shares) | shares		3,030,000
Subsequent Event | License Agreement with Tris [Member]
Subsequent Events
Amount payable on termination, low end of range	$ 6,000
Amount payable on termination, high end of range	9,000
Reduction in amount payable	$ 8,000
Number of installment payments | payment	3
Subsequent Event | Rumpus Earn Out Payments
Subsequent Events
Annual maintenance fee payable				$ 1,500
Issuance of common stock, net of cash issuance costs (in shares) | shares			2,188,940
Milestone payments made			$ 75